



## REVIEW

## Open Access

# LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives

Faisal A Al-Allaf<sup>1,2\*</sup>, Charles Coutelle<sup>2</sup>, Simon N Waddington<sup>2,3,4</sup>, Anna L David<sup>4</sup>, Richard Harbottle<sup>2</sup>, Michael Themis<sup>2,5</sup>

## Abstract

Coronary artery diseases (CAD) inflict a heavy economical and social burden on most populations and contribute significantly to their morbidity and mortality rates. Low-density lipoprotein receptor (LDLR) associated familial hypercholesterolemia (FH) is the most frequent Mendelian disorder and is a major risk factor for the development of CAD. To date there is no cure for FH. The primary goal of clinical management is to control hypercholesterolaemia in order to decrease the risk of atherosclerosis and to prevent CAD. Permanent phenotypic correction with single administration of a gene therapeutic vector is a goal still needing to be achieved. The first *ex vivo* clinical trial of gene therapy in FH was conducted nearly 18 years ago. Patients who had inherited LDLR gene mutations were subjected to an aggressive surgical intervention involving partial hepatectomy to obtain the patient's own hepatocytes for *ex vivo* gene transfer with a replication deficient LDLR-retroviral vector. After successful re-infusion of transduced cells through a catheter placed in the inferior mesenteric vein at the time of liver resection, only low-level expression of the transferred LDLR gene was observed in the five patients enrolled in the trial. In contrast, full reversal of hypercholesterolaemia was later demonstrated in *in vivo* preclinical studies using LDLR-adenovirus mediated gene transfer. However, the high efficiency of cell division independent gene transfer by adenovirus vectors is limited by their short-term persistence due to episomal maintenance and the cytotoxicity of these highly immunogenic viruses. Novel long-term persisting vectors derived from adeno-associated viruses and lentiviruses, are now available and investigations are underway to determine their safety and efficiency in preparation for clinical application for a variety of diseases. Several novel non-viral based therapies have also been developed recently to lower LDL-C serum levels in FH patients. This article reviews the progress made in the 18 years since the first clinical trial for gene therapy of FH, with emphasis on the development, design, performance and limitations of viral based gene transfer vectors used in studies to ameliorate the effects of LDLR deficiency.

## Introduction

Familial hypercholesterolaemia (FH) is primarily an autosomal dominant disorder, characterised by a lifelong elevation of serum cholesterol bound to low-density lipoprotein (LDL). The primary causative defects in approximately 85% of FH cases are mutations or deletions in the plasma membrane Low Density Lipoprotein Receptor (LDLR) encoding gene that is responsible for clearing LDL-cholesterol (LDL-C) from the blood stream by endocytosis and intracellular degradation [1]. Over 1000 different mutations in the LDLR gene on the

distal short arm of chromosome 19 (p13.1-p13.3) have been described to date [2] and are recorded online at <http://www.ucl.ac.uk/ldlr/Current/> [3]. The second gene responsible for fewer than 10% of FH cases encodes the ligand for LDLR, namely Apolipoprotein B-100 (ApoB-100), located on the short arm of chromosome 2 (p24) [4]. Mutations in this gene reduce ligand affinity for the receptors and cause reduced clearance of LDL particles resulting in hypercholesterolemia [5], albeit normal LDLR activity. A mutation in the codon for amino acid 3500 (CGG-to-CAG) was found to be a CG mutation hotspot associated with defective LDLs and hypercholesterolemia [6]. The pathophysiological consequences from LDLR or ApoB mutations are loss of protein function, which lead to monogenic FH. Defects in a third

\* Correspondence: fallaf@uqu.edu.sa

<sup>1</sup>Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Al-Abedia Campus, P. O. Box 715, Makkah 21955, Saudi Arabia  
Full list of author information is available at the end of the article

gene, located on the short arm of chromosome 1 (p34.1-p32), have also been identified to cause monogenic FH [7]. The convertase subtilisin/kexin type 9 (PCSK9)-gene codes for an enzyme that has also been called "neural apoptosis regulated convertase 1", which has been proposed to be involved in degrading the LDLR protein in the lysosome and thus preventing it from recycling [8]. Gain of function mutations in the PCSK9 gene could therefore cause increased degradation of LDLRs, reduced numbers of receptors on the surface of the cell, and monogenic FH. An autosomal recessive form of FH caused by loss of function mutations in the LDLRAP1 gene, which is located on the short arm of chromosome 1p35-36.1, has also been documented [9]. The clinical phenotype of the autosomal recessive form is similar to that of the classic homozygous FH caused by defects in the LDLR gene, but it is generally less severe and more responsive to lipid-lowering therapy (reviewed in [10]). This article focuses on LDLR-associated FH reviewing, the encountered obstacles, the achieved progress and the future prospectives of LDLR-gene therapy for this disease.

#### **LDLR-associated FH**

Owing to mutations in both alleles of the LDLR locus, homozygous LDLR-associated FH patients present with markedly elevated total serum cholesterol (>500 mg/dL, 13 mmol/L) and LDL-cholesterol levels (LDL-C, >450 mg/dL, 11.7 mmol/L). The deposition of insoluble cholesterol causes xanthomata on the tendons of the hands and feet, cutaneous planar and corneal arcus in early life [11,12]. Atheroma of the aortic root and valve can lead to myocardial infarction (MI) and sudden death before the age of 30 years. Coronary artery disease (CAD) is more common and more extensive in receptor negative patients (mutations that completely eliminate receptor functions) than in those with the receptor-defective type (mutations that partially inactivate receptor function), where there is residual receptor activity [12,13]. Heterozygous patients typically have a lower serum cholesterol level (250-450 mg/dL or 6.5-11.6 mmol/L) and LDL-C (200-400 mg/dL or 5.2-10.4 mmol/L) with positive age correlation. They develop the above clinical features at a less accelerated rate, but if untreated most suffer a severe MI and often sudden death or other cardiovascular events in the fourth or fifth decade of life. Due to several hormonal factors, approximately 80% of heterozygote men suffer from CAD, while only 20% to 30% of women are moderately affected [14].

In most investigated populations, the heterozygote form occurs in at least 1:500 and the homozygous form in one in one million individuals [15], although in some populations, for example the Afrikaner population in South Africa, heterozygosity is found in less than 1:80 individuals [16,17]. This unusual high frequency is due


to founder effects and no heterozygote advantage has been identified. Heterozygous FH is therefore the most frequent clinically relevant Mendelian trait, being more frequent than homozygous cystic fibrosis and sickle cell anaemia.

Cholesterol levels alone are not sufficient to confirm a diagnosis of FH because blood cholesterol levels vary with age, gender and are population specific [18]. In addition, the range of blood cholesterol levels in FH overlaps with that of people with non-genetic multifactorial hypercholesterolaemia, which reduces diagnostic accuracy. Diagnostic criteria of FH, therefore, include clinical symptoms and laboratory findings as well as the family history of a dominant pattern of inheritance for either premature coronary heart disease or hypercholesterolaemia, (reviewed in [18]).

The human LDLR is a multi-component single-chain glycoprotein, which contains 839 amino acids in its mature form, encoded by a gene of 45 kb in length [19]. The gene contains 18 exons of which 13 exons code for protein sequences that show homology to other proteins such as the C9 component [20], Epidermal Growth Factor (EGF) [21], blood coagulation factor IX, factor X (FX) and protein C [22-24]. The mRNA transcript is 5.3 kb in length and encodes a protein of 860 amino acids. About half of the mRNA constitutes a long 3' untranslated region that contains two and a half copies of the *Alu* family of middle repetitive DNAs [25]. LDL-Receptors are expressed ubiquitously by almost all somatic cells under control of sterol negative feedback, mediated by three 16 bp imperfect repeats (sterol regulatory elements) and a TATA box like sequence in the promoter [26]. Their function is to bind to apolipoprotein ligands, apoB-100 and apoE. Uptake of LDL is mediated mainly through apoB-100 [27].

The mature human LDLR of 160 kDa is composed of five domains, Figure 1. Exon 1 encodes a short 5' untranslated region and 21 hydrophobic amino acids that are not present in the mature protein. This sequence functions as a signal peptide to direct the receptor synthesising ribosomes to the Endoplasmic Reticulum (ER) membrane [25]. Other functional domains of the peptide correspond to the exons as indicated in Figure 1, 41 bp of exon 17 plus exon 16 encode the transmembrane domain and the remainder of exon 17 together with exon 18 encode the cytoplasmic domain.

Analyses of LDLR-associated FH variants estimated that there were 1066 LDLR gene mutations/rearrangements, 65% (n = 689) of which were DNA substitutions, 24% (n = 260) small DNA rearrangements (<100 bp), and 11% (n = 117) large DNA rearrangements (>100 bp) [2]. The DNA substitutions and small rearrangements occur along the length of the gene, with 839 in the exons (93 nonsense variants, 499 missense variants and 247 small



rearrangements), 86 in intronic sequences, and 24 in the promoter region. The highest proportion of exon variants occurs in the ligand binding domain (exons 2-6) and the EGF precursor domain (exons 7-14) [2].

#### Clinical management of FH

To date there is no cure for FH. The primary goal of clinical management in heterozygotes is to control hypercholesterolaemia by lifestyle modification and/or

drug treatment in order to decrease the risk of atherosclerosis and to prevent CAD. Lifestyle modification involves educating patients to adhere to a low-fat diet, exercise and to reduce overweight or maintain an optimal body weight. An effective low-fat diet could lower LDL-C (LDL cholesterol) by 20% to 30% [28-30]. For patients who are not able to reach their LDL-C goal (<129 mg/dL, 3.31 mmol/L) on the lifestyle modification program, drug therapy is the next step. The current recommendations for LDL-C goals from the National Cholesterol Education Program Adult Treatment Panel III guidelines are <100 mg/dL, 2.586 mmol/L for patients with very high cardiovascular risk and <129 mg/dL, 3.31 mmol/L for patients with moderate cardiovascular risk [31]. The preferred and most effective lipid-lowering agents are the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, more commonly known as statins [32]. Statins are the best tolerated medication in patients of all ethnic groups, both sexes, and generally, all ages. They also have an excellent safety profile over the now nearly 20 years of widespread clinical use, and have the highest level of patient adherence among available lipid-lowering agents with low incidence of side effects [33]. Because different statins have variable potency, the therapeutic outcome ranging from 20% to 60% reduction in LDL-C [32], depends on the particular statin used, the dose and the type of LDLR mutation. Despite the powerful effect of statins, they may not be appropriate for those who are best treated with non-systemic therapy (eg, young adults, women of childbearing age), who require only a modest reduction in LDL-C, or those with active liver disease or increased liver function test values and who predominantly have hypertriglyceridemia. Increasing the statin dose to 80 mg (rosuvastatin to 40 mg) is associated with a threefold increase in liver toxicity or myopathy [34]. Therefore, treatment with non-statin cholesterol lowering agents, for example bile acid resin [35], niacin [36], fibrate [37] or cholesterol absorption inhibitor [38], is recommended for these patients.

Bile acid binding resins are non-absorbable anion exchange resins that bind bile acids in the intestinal lumen, preventing their absorption from the ileum and therefore increasing their fecal excretion. The liver responds by up-regulating cholesterol 7-alpha hydroxylase, which increases the conversion of cholesterol to bile acids, thereby reducing the cholesterol concentration in the hepatocyte [39]. Gastrointestinal disturbances, and drug and/or fat-soluble vitamin malabsorption, which were associated with early generation bile acid resins, have been overcome with new generation agents [35]. Bile acid resins can lower LDL-C approximately 10% to 25% which is appropriate for patients who need only moderate LDL-C lowering [35].

Niacin, or nicotinic acid, is the oldest lipid-lowering drug dating back to the 1950s [39]. Depending on dose and formulation, LDL-C reductions of 12% to 20% maybe anticipated, along with good reductions in triglycerides and 17% to 31% increase in high-density lipoprotein cholesterol (HDL-C). The major drawback to niacin use is its side effects, which include itching, headaches and hepatotoxicity. It is contraindicated in patients with active liver disease or unexplained abnormalities in liver function tests [39].

A cholesterol absorption inhibitor, more commonly known as Ezetimibe, impairs dietary and biliary cholesterol absorption at the brush border of the intestine without affecting the absorption of triglycerides or fat-soluble vitamins [19]. It has been shown to be well tolerated and effective in lowering LDL-C when used as a monotherapy or when adding to statin therapy. Ezetimibe at a dose of 10 mg/day reduced LDL-C by approximately 17% with no adverse effect of myopathy or liver toxicity [40,41]. However, recently concerns have been raised in respect to an independent atherogenic property of this drug, which appears to counteract its cholesterol-reducing action [42].

For patients who do not respond to a maximum dose of a statin and those who develop side effects with higher doses, a combination therapy of statin with one of the above agent, rather than an increase in the statin to high doses, may be more effective in achieving LDL-C goals and improving CAD outcomes while remaining at an acceptable safety profile [43]. Adding a bile acid resin or niacin to the statin can reduce LDL-C by approximately 50%, depending on the choice of statin and dosage prescribed [44,45]. Co-administering 10 mg of ezetimibe with any dose of statin reduced LDL-C levels by an additional 25%, compared with the usual 6% attained by doubling the statin dose [46]. However, even after treatment with a combination therapy, the majority of homozygous and minority of heterozygotes FH patients may still have extremely raised LDL-C serum levels [47] and their risk of CAD remains unacceptably high.

Surgical interventions involving a portocaval shunt or an ileal bypass have yielded transient lowering of plasma LDL in these patients [48]. The preferred treatment at present is an aggressive programme of plasma apheresis or LDL apheresis, a physical procedure in which LDL is selectively removed from the blood by passing plasma over columns that bind the LDL. A small number of angiographic regression studies have been conducted and each weekly or fortnightly treatment has been demonstrated to lower LDL-C levels by about 55% and to delay onset and progression of atherosclerosis [49-53].

The most significant but also most aggressive metabolic correction is orthotopic liver transplantation in homozygous patients [54-56]. However, the morbidity

and mortality risks as well as scarcity of donated organs are serious limitations.

Several novel therapeutic approaches have also been developed recently to lower LDL-C, either as monotherapy or in combination with statins [57] including; squalene synthase inhibitors [58], microsomal triglyceride transfer protein inhibitors [59,60], siRNA for PCSK9 [61] or for apolipoprotein B-100 [62] silencing, antisense PCSK9 [63], and antisense apolipoprotein B-100 (more commonly known as Mipomersen sodium (ISIS 301012)) [64,65].

In August 2010, Genzyme Corp. and Isis Pharmaceuticals Inc. announced the completion of the four phase 3 clinical trials that are required in the initial United States and European of regulatory filings for mipomersen. Filings for therapeutic use in homozygous FH are expected in the first half of 2011 [66]. These double-blinded, placebo-controlled clinical trials have been conducted at several locations worldwide. They involve heterozygous FH patients [67], homozygous FH patients [68], and patients with severe hypercholesterolemia [69]. The latter are defined by LDL-C levels  $\geq 200$  mg/dL and baseline cardiovascular disease (CVD) or by LDL-C levels  $\geq 300$  mg/dL without CVD. The trials also include patients with high cardiovascular risk [70] and high cholesterol levels as defined by LDL-C levels  $\geq 100$  mg/dL who were already taking maximally tolerated lipid-lowering medications.

At the end of the study, these patients had an average LDL-C reduction of 36-37% with no serious adverse effects. The reductions observed in the study were in addition to those achieved with the patients' existing maximally tolerated statin regimens. The trial also met each of its three secondary endpoints with statistically significant reductions in apo-B, non-HDL-cholesterol and total cholesterol. All trials also demonstrated manageable safety and tolerability profile of mipomersen.

Although each of these novel therapies effectively lowers LDL-C, challenges remain for clinical development in the assessment of long-term safety.

### Liver directed gene therapy for FH

Patients who have undergone liver transplantation and have experienced substantial reductions in LDL-C levels provide indirect evidence that gene therapy targeted towards the liver could be effective for this disease. While LDLR is expressed by the majority of body cells, hepatic reconstitution of LDLR expression alone may be sufficient for metabolic correction [71,72]. The liver is an attractive organ for FH gene delivery because of its large mass, its ability to synthesise large amounts of proteins, its central position in metabolism and its good accessibility through the portal vein [72,73].

The homozygous form of FH would be an excellent candidate for gene therapy since the plasma lipid profile, total

cholesterol, LDL-C, HDL-C and LDL/HDL ratio, can be measured providing a convenient clinical endpoint to evaluate the response to therapy [71,72]. In addition, a sensitive non-invasive method using a scintillation camera is available to determine the location, magnitude, and duration of LDLR transgene expression which could provide functional transgene expression in gene therapy trials of FH [74]. Moreover, animal models are available, which include the Watanabe heritable hyperlipidemic (WHHL) rabbit [75], and rhesus monkeys [76], the ApoE-knockout (ApoE<sup>-/-</sup>) mouse [35], and the LDLR-knockout (LDLR<sup>-/-</sup>) mouse models [77]. The WHHL rabbit demonstrates hypercholesterolaemia due to natural deletion of 12 nucleotides in the LDL-binding domain of the LDLRcDNA [78]. This causes a delay in the post-translational processing of the 120 kDa LDLR-precursor to the 160 kDa mature form, leading to premature degradation of the mature form in the cytoplasm and consequently hypercholesterolaemia (700-1200 mg/dl at 12 months of age) [79]. The WHHL rabbit, therefore, demonstrates metabolic and clinical abnormalities similar to those in patients with FH and may be a more authentic FH model than the LDLR<sup>-/-</sup> or ApoE<sup>-/-</sup> mouse models [80] where the raised plasma cholesterol levels ( $225 \pm 27$  mg/dl) are lower unless the animals are subjected to a high cholesterol diet. There are also some intrinsic differences in the lipoprotein metabolism of mice compared to humans and rabbits. For instance, the main lipoprotein in plasma of FH patients and the WHHL rabbit is LDL, but in ApoE<sup>-/-</sup> mice [81] it is the VLDL fraction with apoB-48, and HDL and LDL in LDLR<sup>-/-</sup> mice [77]. The activity levels of the plasma cholesterol-ester transfer protein (CETP), which facilitates the transport of cholesteryl esters and triglycerides between the lipoproteins, and hence plays a role in LDL particle remodelling, are high in WHHL rabbits, although murine models lack this activity [80,82]. Consequently, HDL levels in the plasma are low in WHHL rabbits but high in mice and rats. In contrast, the ApoB-editing enzyme is not expressed in the liver of rabbits [80], but murine models do have ApoB-editing activity in the liver [81]. Therefore, apoB-48-containing VLDL is secreted from the liver in mice [80,81]. Selective breeding of WHHL rabbits resulted in coronary atherosclerosis-prone WHHL rabbits manifesting with features of coronary and aortic atherosclerosis and myocardial infarction, in contrast murine models are usually resistant to the development of myocardial infarction and features of coronary and aortic atherosclerosis [80]. For the above-described differences, the WHHL rabbit is thought to be a more authentic FH model similar to human subject (reviewed in [80]).

### Methods of gene delivery

Gene transfer can be performed either *ex vivo*, involving isolation of autologous cells from the patient, their *in vitro* genetic modification and selection followed by

reimplantation of the transduced cells, or it can be done *in vivo*, where the vector is delivered directly to the organ [83]. The advantage of the *ex vivo* approach is that the transduction/transfection conditions can be carefully controlled and optimised and individual clones with the most desirable characteristics can be isolated to eliminate unmodified cells or cells with deleterious mutations before re-implantation. While this approach is laborious and time consuming, it may also offer significantly greater safety and control with respect to vector mediated mutagenesis and possible germline transmission of the transferred genes, which is a risk of *in vivo* gene delivery. The disadvantages of the *ex vivo* approach are failure of cell engraftment and difficulties in returning the cells to the patient due to disease manifestations such as portal vein hypertension [83,84].

The *in vivo* approach eliminates the need for engraftment after re-implantation and is therefore easier to perform, more cost effective and may be more applicable for use in countries with limited laboratory resources. The gene transfer vector is injected into the bloodstream (systemic delivery) aiming at somatic cell delivery only or by use of specific cell targeting, preferentially to the tissues of interest (targeted delivery). Organ specific delivery of the gene transfer vector includes intrahepatic injection or selective intravascular application routes. Disadvantages of *in vivo* gene transfer are vector dilution, ectopic transgene expression and non-targeted, random, potentially genotoxic insertion into the host genome.

### Gene transfer systems

In addition to the method chosen for delivery, successful treatment of FH would ideally require safe and efficient gene transfer vectors that provide appropriate and sustained levels of transgene expression and long-term survival of treated cells. The use of a liver specific promoter would be the most physiological approach to achieve this. However, because of present problems in transfection-efficiency, strong heterologous promoters are commonly used instead for proof of principles studies on the effectiveness of lipid-lowering. The development of more effective vectors to achieve this remains a formidable challenge to gene therapy. The properties required of such a vector system and those that should be avoided are listed in Table 1.

Gene transfer vectors are generally classified under two categories; they are either non-viral or virus mediated gene transfer systems.

### Non-viral gene transfer systems

Gene therapy vectors based on modified viruses are unquestionably the most effective gene delivery systems in use today. Their efficacy at gene transfer is however

tempered by their potential toxicity [85,86]. An ideal vector for human gene therapy should deliver sustainable therapeutic levels of gene expression without compromising the viability of the host (at either the cellular or somatic level) in any way. Non-viral vectors are attractive alternatives to viral gene delivery systems because of their low toxicity, relatively easy production and great versatility [87].

Most of the non-viral vectors that have been described for gene therapy are based on complimentary DNA (cDNA) gene sequences driven by highly active promoters. The DNA in these vectors is typically formulated with cationic agents to form complexes, which protect the DNA and facilitate cell entry [87,88]. DNA can, however, be driven into cells by physical means and the liver is particularly amenable to gene delivery via hydrodynamic delivery. Mahato *et al* reported that a standard tail vein injection of naked DNA into mice resulted in almost no gene expression in major organs due to its rapid *in vivo* degradation by nucleases and clearance by the monocular phagocyte system [89]. However, a very rapid injection of a large volume of naked plasmid DNA solution (e.g. 5-10 µg of DNA in 2.5 ml saline, which is almost equivalent to the blood volume of the animal, within 5-7 seconds) *via* the same route induced efficient gene transfer particularly in the liver [90]. This procedure was applied in one of the first non-viral approaches to reverse hypercholesterolaemia in an FH model. In these experiments a DNA construct was produced which encoded a fusion-protein consisting of a soluble form of the LDLR combined with transferrin. The strategy of this approach was based on the ability of the fusion protein to be capable of binding both plasma LDL and the cellular transferrin receptor. When applied *in vivo* following hydrodynamic injection [91], this protein was shown to bind circulating plasma LDL and to mediate its clearance through the transferrin receptor on hepatocytes. Although the system proved functional, a statistically significant change in the lipoprotein profile of an animal model was not demonstrated and the possible immunogenicity of the fusion protein potentially precludes its utility.

In contrast to using a cDNA expression cassette, the use of a complete genomic DNA locus to deliver an intact transgene with its native promoter, exons, all intervening introns, and regulatory regions with flanking non-coding genomic DNA sequences may allow regulated complementation of LDLR deficiency in the liver of hypercholesterolaemic animals. In 2003, a bacterial artificial chromosome containing the entire LDLR genomic locus and based on the Epstein Barr Virus (EBV)-retention system was delivered to LDLR deficient Chinese hamster ovary cell line (CHOIdA7) [92], and achieved correction of the cells' deficiency phenotype

**Table 1 The properties required for development of an ideal vector system and those that need to be avoided.**

Properties needed	Properties to be avoided
Stable high titre vectors	Vector degradation
Simple and reproducible production	Replication competent virus
Unlimited packaging capacity	Expression of undesirable viral proteins
Efficient gene transfer to the target cells	Germline gene transmission
Controlled genomic integration	Insertional mutagenesis
Regulated normal levels of expression	Inappropriate toxic expression
Ability to repeat delivery if needed	Severe immune response against vector system
Long-term expression	Immune response against transgene products

[93]. This vector construct was able to mediate LDLR expression at significant levels in the CHOldIA7 cells and in human fibroblasts derived from FH patients for 3 months and to retain the classical expression regulation by sterol levels in these cells. These initial studies paved the way for the development a more sophisticated vector which utilised a Scaffold Matrix Attachment Region (S/MAR) rather than a potentially toxic viral component to provide episomal maintenance [94]. In this study the LDLR genomic locus was incorporated into an HSV-1 amplicon vector, which was shown to remain episomal for 11 weeks and provided the complete restoration of human low density lipoprotein receptor LDLR function in CHOldIA7 cells to physiological levels. The vector comprised the LDLR gene driven by 10 kb of the human LDLR genomic promoter region including the elements, which are essential for physiologically regulated expression. By utilizing the genomic promoter region it was demonstrated that long-term, physiologically regulated gene expression and complementation of receptor deficiency could be obtained in culture for at least 240 cell-generations. Importantly, this vector was shown to be sensitive to the presence of sterols or statins, which modify the activity of the LDLR promoter. These *in vitro* studies finally lead to the successful administration of genomic LDLR vectors *in vivo* via hydrodynamic delivery [95,96]. When administered hydrodynamically in mice it was demonstrated that efficient liver-specific delivery and statin-sensitive expression could be obtained for up to 9 months following delivery [96].

While the majority of studies were focused on treating FH by inhibition of hypercholesterolaemia through up-regulation of LDLR or other surrogate lipoprotein receptors (as will be discussed later), an alternative approach was to down-regulate apoB-100 LDLR-ligand or PCSK9 [63] expression. Down-regulation of apoB-100 by continuous intravenous/subcutaneous administration of Mipomersen antisense apolipoprotein B-100 oligonucleotide had been attempted in several clinical trials achieving average LDL-C reduction of 36-37%. Although, the most

common adverse event of these trials was erythema at the injection site due to the protocol [64,65,97-102], challenges remain for clinical development in the assessment of long-term safety.

### Recombinant virus-based gene transfer systems

Recombinant viral vectors are usually more effective than non-viral vectors in mediating cell entry and nuclear transfer of therapeutic genes in the target cells. In addition natural tropism of viral envelopes and serotypes can be employed to achieve targeting selectivity for particular host cells. Most of these vectors have mechanisms to avoid intracellular degradation and overcome cellular and immunological barriers to the delivery of the genetic cargo. Generation of a virus vector requires the transformation of a potentially harmful virus from a pathogen into a gene transfer agent whilst retaining the viral infectivity. Hence, the first step is to make the vector replication defective (incapable of producing infectious viral particles in the host's target cells). Replication deficient viral vectors are developed by deletion of crucial genes in the virus genome, which are then generally replaced by the therapeutic gene. The elements removed in this way have to be provided *in trans* in order to support vector production. This can be achieved by use of a helper virus or a packaging (production) cell line transfected with the plasmids expressing the genes coding for the required structural virus components and replication proteins. Helper virus must be purified away from the final vector batches intended for safe gene delivery.

Recombinant viral vectors presently used are generally classified under two categories; integrating or non-integrating viral vectors [103]. This distinction is an important determinant of the suitability of each vector for a particular application. Present integrating vectors rely on random insertion of the transgenic DNA into the cell's genome, leading to stable integration and subsequent passage to the cell's progeny. This gene insertion via non-homologous end joining of vector DNA to that of the host using a virus integrase can be most

efficiently achieved using retroviral or lenti-retroviral vectors. Adeno-associated viral vector integration is less frequent than that of the unmodified parent virus, which targets preferentially into chromosome 19 and does not show the locus specificity of wild-type virus. It is important to note that integration does not guarantee stable transgene expression due to host mediated gradual silencing of gene expression over time [104], immuno-elimination or physiological cell death of gene modified cells.

Non-integrative vectors such as adenovirus and herpes simplex viral vectors allow transient episomal expression of a foreign gene in the target cells. Because of their episomal maintenance, the transferred genes are usually lost over time by dilution at cell division in actively dividing cells or by degradation in non-dividing cells [105]. A non-integrative vector could ideally be delivered repeatedly if required, as long as no immunological reactions develop against the vector or transgenic protein. Unlike adenovirus and herpes simplex viruses, EBV is stably maintained without integration in permissive proliferating cells due to the EBV nuclear antigen 1 protein-mediated replication and segregation, providing long-term transgene expression [106]. It is however unlikely to be used in a clinical setting due to its association with Burkitt's lymphoma. The properties of the most commonly used viral vectors are summarised in Table 2.

### Retrovirus based vectors

Retroviruses (RVs) are a large family of enveloped RNA viruses, which are generally classified into three subfamilies; oncoretroviruses, lentiviruses and spumaviruses (foamy viruses). The RV particle is composed of two copies of an RNA genome held together primarily by a sequence called the dimer linkage, which is termed the leader region and found in some cases in *gag* coding region. The genome is surrounded by a spherical or cylindrical shaped core and an enveloped glycoprotein, (Figure 2-A). Upon infection, RVs are able to convert their RNA genome in the host cytoplasm to DNA through reverse transcription (RT) [107].

The genome size of simple RVs is approximately 8-12 kb and comprises three main genes; the group specific antigen encoding gene (*gag*), the polymerase encoding gene (*pol*), and the envelope glycoprotein encoding gene (*env*), which are flanked by elements called long terminal repeats (*LTRs*), Figure 2-B. The *gag* gene encodes the viral structural core proteins, which form the matrix, capsid and nucleocapsid, generated by protease cleavage of the Gag precursor protein. The *pol* gene expresses a complex of enzymes that are involved in particle maturation (protease), DNA metabolism (reverse transcriptase) and proviral integration (integrase). These enzymes are usually derived from the Gag/Pol precursor.

The *env* gene encodes the surface glycoprotein and the transmembrane protein of the virion, which form a complex that interacts specifically with cellular receptor proteins. The genes in the viral DNA are bracketed by the *LTRs*, which define the beginning and the end of the viral genome. The *LTRs* are identical sequences that can be divided into three elements. *U3* is derived from a sequence unique to the 3' end of the RNA, *R* is derived from a sequence repeated at both ends of the RNA, and *U5* is derived from a sequence unique to the 5' end of the RNA. The genesis of the *LTR* elements lies in the process of reverse transcription. *U3* contains most of the transcriptional control elements of the provirus (viral genome, which has integrated into the chromosomal DNA of a cell), which include the promoter and multiple enhancer sequences responsive to cellular and in some cases viral transcriptional activator proteins. The site of transcription initiation is at the boundary between *U3* and *R* of the 5' *LTR* and the site of poly(A) addition is at the boundary between *R* and *U5* at the 3' *LTR*, as shown in Figure 2-C. The other boundaries of *U3* and *U5* are determined by the primer binding site (*PBS*) and the polypurine tract (*PTT*), which are important for reverse transcription. Just downstream of the 3' end of the 5' *LTR*, is a short packaging sequence (*Psi*, $\Psi$ ), which extends into *gag* and is responsible for encapsidation of the two viral RNA genomes into the capsid. The *att* sequences at the ends of the 5' and 3' *LTRs* are necessary for proviral integration [107].

The life cycle of a RV starts with high affinity binding of the viral envelope glycoprotein to its receptor on the outer layer of the cell membrane. This interaction leads to the fusion of the lipid envelope surrounding the virus, with the target cell membrane. Cell entry of the viral capsid containing the RNA genome allows the reverse transcriptase enzyme to copy the viral RNA genome into a double-stranded DNA, which becomes associated with viral proteins to form what is called a pre-integration complex (PIC). The PIC translocates to the nucleus where the viral enzyme integrase, which is part of PIC, mediates integration of the provirus DNA sequence into the chromosomal DNA of the host cell. The inserted sequence (provirus) is flanked by complete copies of *LTR* sequences. The 5' *LTR* drives transcription of the RV genome, which gives rise to RNA that codes for the viral proteins Gag, Pol and Env as well as for the viral RNA genome, Figure 2-C. Gag and Gag/Pol proteins assemble as viral core particles at the plasma membrane which package the viral RNA genomes and bud from the cell membrane enveloped with plasma membrane lipid from the host, in which virus derived Env glycoproteins are embedded [107].

The first generation replication defective retroviral vectors were developed using Molony Murine



**Table 2 General properties of the most commonly used viral vectors.**

Properties	Adenoviruses	AAV	Retroviruses	Lentiviruses
<b>Wild type viruses</b>	36 kb ds linear DNA	4.7 kb ssDNA	9.2 kb Diploid +ssRNA	8-10 kb Diploid +ssRNA
<b>Pre-existing host antibodies</b>	Yes	Yes	Unlikely	Unlikely but (may be in HIV +ve individuals)
<b>Packaging capacity</b>	8-30 kb	4 kb	<8 kb	8 kb expected
<b>Viral titre (particles/ml)</b>	>10 <sup>13</sup>	>10 <sup>12</sup>	>10 <sup>9</sup>	10 <sup>9</sup>
<b>Stability</b>	Good	Good	Good	Not tested
<b>Integration</b>	No	<10% integrated	Yes	Yes
<b>Cellular localisation</b>	Nuclear	Nuclear	Nuclear	Nuclear
<b>Cell range</b>	Non-replicating and replicating	Non-replicating and replicating	Replicating only	Non-replicating and replicating
<b>Levels of expression</b>	Very high	Moderate	Moderate	Moderate
<b>Duration of expression</b>	Transient	Long	Long, but subject to shutdown	Long
<b>Immune response</b>	Extensive	Not known	Few neutralising antibodies	Not known
<b>Safety issues</b>	Inflammatory and toxicity	Rearrangement and inflammatory	Insertional mutagenesis	Insertional mutagenesis
<b>Main advantages</b>	Extremely efficient transduction of most tissues	Non-inflammatory Non-pathogenic	Long-term gene transfer in dividing cells	Long-term gene transfer in dividing cells
<b>Main disadvantages</b>	Capsid mediates a potent inflammatory response	Small packaging capacity	Transduces only dividing cells and potential for oncogenesis	Potential for oncogenesis



kb, kilo base; ssDNA, single stranded DNA; dsDNA, double stranded DNA.

Leukaemia Virus (MoMLV) as a prototype. Replication defective vector particles were produced by a deconstruction strategy, which aims to dissect/segregate the viral genome into two transcriptional units (plasmid constructs). They are the vector genome and the packaging constructs, Figure 3. The vector genome retains all the necessary *cis* elements of the vectors and is generated by replacing viral protein encoding sequences later to be provided in *trans* with the transgene of interest. Both the  $\Psi$  signal that is essential for packaging of the vector genome into the capsid and the viral *LTRs*, which are necessary for proviral integration, remain in the vector genome construct. Expression of the transgenic protein is driven by the promoter in the *U3* region of the 5' *LTR*. The packaging construct provides all of the viral proteins in *trans* to the vector genome construct (Gag, Pol and Env). The packaging signal is deleted from the packaging construct to prevent its incorporation into viral particles. When both the vector genome and packaging constructs are present in a producer cell, retroviral vector particles, which are capable of delivering the vector genome with its inserted gene into new target cells, are released [108]. The process of gene transfer by such a vector is referred to as transduction. When these two constructs are present in cells in an integrated form, the cell becomes a stable virus producer.

Alternatively, virus can also be produced for a short period of time after transient co-transfection of the viral genome alongside with packaging plasmids.

The basic arrangement described above is functional but unsatisfactory for several reasons. Firstly, the sequence overlap that remains between the vector and packaging constructs could result in recombination to form infectious replication competent retrovirus (RCR). The overlap exists principally because extensive sequences of the *gag* gene are retained in the vector construct to enhance the efficiency of packaging, although Gag protein production is prevented by mutation. In addition, overlapping sequences also exist because the *LTRs* are retained in the packaging construct to provide both promoter and poly-adenylation sequences. Secondly, the early MoMLV based vectors were established in murine NIH 3T3 packaging cell lines, therefore, the possibility for RCR generation through recombination between vector constructs and defective endogenous MoMLV-like sequences present in the target cells cannot be excluded [109]. Thirdly, vector particles produced in murine cells can be sensitive to host complement mediated inactivation after *in vivo* gene delivery [110,111].

In order to minimise the risk of RCR production, an improved vector system was designed by segregating the



*gag/pol* and *env* genes present on the packaging construct, onto discrete expression units, Figure 4. The risk of recombination was also further reduced by the use of heterologous envelope proteins that are derived from alternative viruses with no homology to parental virus sequences but are still able to be incorporated into the viral particle (a process referred as pseudotyping). Pseudotyping may also alter the tropism of the viral vector and can be used as a powerful tool for cell targeting different host tissues. Pseudotyping of MoMLV and other RVs with the murine ecotropic (recognising only receptors present on mouse cells), amphotropic (interacting with receptors on both mouse and human cells) or the vesicular stomatitis virus glycoprotein (VSV-G) envelopes (with broad host range including mammalian and even insect cells) has been achieved and proven useful [112,113]. In this improved virus production system, part of the *gag* sequence present on the first generation MoMLV vector is removed from the vector genome without significant loss of packaging efficiency (it was subsequently found that part of the *gag* region is essential for efficient vector packaging) [114], Figure 4.


The problem of overlapping sequences between the vector and the packaging construct has been solved by using heterologous promoters and polyadenylation signals to drive structural gene expression from the packaging constructs. Strong heterologous promoters like cytomegalovirus (CMV) can provide high virus titre production circumventing the limited titre offered by the MoMLV *LTRs* that give low-level gene expression in producer cell lines not of murine origin. In the vector genome construct itself, heterologous promoters have been used to replace the 5' *U3* promoter. In addition, the 3' *U3* sequences can be significantly deleted as long as the sequences necessary for recognition by the integrase protein are retained. This is the basis of self-inactivating (SIN) vectors where deletion of the viral

promoter and enhancer regions in the 3' *U3* are duplicated during reverse transcription in the 5' *LTR* to prevent *LTR*-driven transcription in infected host cells which could result in the expression of downstream inserted proto-oncogenes [115]. Transgene expression in these vectors is therefore typically and exclusively driven by an internal heterologous promoter, which allows the use of regulated and/or tissue specific expression. Finally, a non-murine producer cell line was used for vector production to prevent the possible generation of RCR through recombination with endogenous MoMLV-like sequences [110].

In the latest generation of RV based-vectors, improvements have also been made in the vector titre (number of colony-forming units per ml) by the development of transient plasmid co-transfection systems, which are capable of producing very high vector titres for a short period of time in the highly transfectable HEK 293 (human embryonic kidney epithelial cells) cell line [110]. Also some human cells used to generate packaging cell lines can produce a complement-resistant retroviral vector [111]. Transfection of HEK 293T cells using SV40 large T antigen to improve vector load and hence vector titre are used also to circumvent the cytotoxicity of the highly desirable VSV-G envelope that provides broad host range infection.

Recombinant MoMLV-based vectors produced by the strategy described above are efficient gene transfer vehicles, reaching transfer levels *in vitro* of close to 100%. They can be produced at a high titre ( $10^9$  infectious units (IU)/ml) and have the capacity to infect a wide variety of dividing cells including hepatocytes. The RV vector genome can also provide transfer of RNA of approximately 7.5 kb in length.

The critical limitation to the use of RVs is their inability to infect non-dividing cells and as the liver is an only slowly proliferating tissue these vectors are not ideal for



**Figure 4** Schematic representation of the improved retrovirus three plasmid co-transfection system. Viral genome is segregated into three expression plasmids; the vector genome, the Gag/Pol expressing plasmid, and the envelope expressing plasmid. For generation of viral particles, these plasmids are co-transfected into the HEK 293 producer cells, and virus is released into the supernatant.

LDLR gene delivery to hepatocytes. Therefore, for direct *in vivo* transduction of the liver, cells have to be either in a naturally dividing state or to be induced to divide. Alternatively, the vectors can be used for *ex vivo* treatment.

Hypercholesterolaemia has been ameliorated by RV-based vectors using *ex vivo* gene delivery in numerous experimental studies. The original procedure used for liver-directed gene therapy of FH was based on the *ex vivo* approach, which involved re-infusion of autologous hepatocytes that had been removed from a WHHL rabbit and subjected to *in vitro* genetic correction with RV vectors based on MoMLV. Animals transplanted with LDLR transduced cells demonstrated a 30-50% reduction in total serum cholesterol levels persistent for the duration of the experiment (122 days). Recombinant derived LDLR mRNA was detected in liver cells for 6 months. There was no apparent immunological response to the recombinant derived rabbit LDLR [116]. This study illustrated the potential of the *ex vivo* approach to ameliorate hyperlipidaemia associated with FH using a RV-based vector.

In preparation for human trials with RV-based vectors, the efficacy, safety and feasibility of *ex vivo* gene therapy for FH was further documented in non-human primates [117,118]. Three baboons were subjected to a partial hepatectomy and their hepatocytes were isolated, cultured, and transduced with a RV containing the human low-density lipoprotein (hLDLRcDNA) sequence. Infusion of the genetically modified hepatocytes was performed through a catheter that had been placed into the inferior mesenteric vein at the time of liver resection. The baboons tolerated the procedures and were monitored for up to eight months [117]. The safety and efficacy of the *ex vivo* approach for delivery of gene transduced hepatocytes via the mesenteric circulation was further documented in a canine model [118].

The above studies demonstrated the feasibility and safety of the *ex vivo* approach, which was then carried out on a human patient in the first clinical trial for FH published in 1994. In this trial a 29 year-old woman with a homozygous receptor defective FH was subjected to *ex vivo* gene therapy using an amphotropic RV-based vector expressing human LDLRcDNA under control of the CMV enhanced chicken  $\beta$ -actin promoter. The patient tolerated the procedure and *in situ* hybridisation of liver tissue four months after therapy revealed evidence for engraftment of transgene expressing cells. The patient's LDL/HDL ratio declined from 10-13 before vector delivery to 5-8 after vector delivery, an improvement that remained stable for the duration of the reported observation (18 months). However, kinetic studies of LDL metabolism including LDL binding, uptake and degradation were not presented [119]. This trial was

severely criticised with respect to both the suitability of the patient for this therapeutic intervention and for the aggressiveness of the protocol, which involved a 25% hepatectomy [120].


Grossman et al then reported four additional homozygous FH patients subjected to a surgical resection of the left lateral segment of the liver and re-infusion of the genetically modified hepatocytes [121]. The patients tolerated the infusions of autologous hepatocytes well without complications. Liver biopsies performed four months after treatment revealed LDLR transgene expression in a limited number of hepatocytes by *in situ* hybridisation in all four subjects. One of four patients had a significant and prolonged reduction of about 20% in his LDL-C levels. Kinetic studies of the LDL metabolism demonstrated that LDL catabolism was increased in the same patient, which was consistent with increased LDLR expression [121]. The reason for the only marginally successful lowering of cholesterol levels and the variable metabolic responses observed in the five subjects studied are presumably due to low gene transfer efficiency or low expression levels [121]. The variable metabolic response observed following low-level genetic reconstitution in the five patients precluded a broader application of *ex vivo* liver-directed gene therapy with RV based vectors, pending improvement of vector efficiency. The following sections review the preclinical work towards this goal with alternative vector system.

#### Adenovirus based vectors

Adenoviruses (Ads) are icosahedral particles consisting of linear, double stranded DNA with a non-enveloped virion, (Figure 5-A). There are at least 50 different human adenovirus serotypes with an approximate genome size of 36 kb. The Ad genome (Figure 5-B) is intimately associated with viral proteins (core) and is packaged in the viral capsid, which consists primarily of three proteins; hexon, penton base and fibre-knob. After infection, the virus genome does not integrate into the host chromosomal DNA, instead it is replicated as an episomal (extra-chromosomal) element in the host nucleus [122].

Because of the ability of adenoviral vectors to infect a broad range of mammalian cell types regardless of their replication status, they have been widely used for a variety of gene transfer applications *in vitro* [123], *in vivo* [124] and in clinical trials [125]. Most adenoviral vectors currently used are derived from serotypes 2 or 5, which are endemic and cause upper respiratory tract infection in humans. Most human individuals have become immune-sensitised by natural infection during childhood [83].

Vectors derived from serotypes 2 and 5 enter the cells after attachment to the cellular receptor CAR (coxsackievirus and adenovirus receptor), through the knob of



**Figure 5 Features of adenovirus particle.** A.) Structural features of Ad. B.) Genomic organisation of wild type Ad. Reproduced with modifications from original diagram provided kindly by Dr Simon Waddington.

the fiber [126]. Virus entry occurs then through clathrin-mediated endocytosis after binding of the penton base to integrins [127]. It is noteworthy that differences in the tropism of various Ad serotypes indicate that besides CAR, other cellular receptors also contribute, suggesting that the host range of Ad vectors can be altered by use of alternative serotypes.

The first generation of replication deficient Ad vectors was constructed by replacing one or two viral early (E1 and E2) genes, which are essential for viral replication, with the transcriptional cassette of interest containing an enhancer-promoter element and the desired gene. Vectors in such a configuration have a packaging capacity of 6.5-8.3 kb. The recombinant vectors are replicated in cells that express the products of the E1 and/or E2 genes. Purified high titre stocks of  $10^{11}$ - $10^{12}$  Ad particles per ml, can be generated and allow high efficiency Ad mediated gene transfer with strong tropism for the liver. Cells that were transduced with these vectors express adenoviral genes at low levels, in addition to the transgenic protein [128].

The utility of replication defective first-generation recombinant Ad to mediate hLDLR gene transfer in hepatocytes derived from FH patients was first examined and documented in 1993 [123], using the  $\beta$ -actin promoter. The level of recombinant-derived LDLR protein

in transduced FH hepatocytes exceeded the endogenous levels by at least 20-folds.

Reversal of hypercholesterolaemia was then demonstrated in LDLR<sup>-/-</sup> mice fed with a high cholesterol diet after intravenous injection of a replication-defective Ad encoding the hLDLR driven by CMV promoter. This *in vivo* approach resulted in reduction of the elevated intermediate density lipoprotein (IDL)/LDL ratio to normal levels, four days after vector delivery [129]. Similarly, injection of a replication-defective Ad encoding the hLDLR driven by an optimised CMV promoter into the portal vein of WHHL rabbits, resulted in over-expression of hLDLR in the majority of hepatocytes that exceeded the levels in normal human liver by at least 10 fold. Transgene expression was stable for 7-10 days but diminished to undetectable levels within three weeks [130]. Similar studies were also conducted on WHHL rabbits with Ad vectors containing rabbit LDLRcDNA [131] or human LDLRcDNA [132]. These studies also resulted in strong but transient transgene expression. However, the high level of LDLR expression and substantial reduction of total and LDL cholesterol achieved by adenovirus LDLR gene transfer in these animal models led to a massive intracellular lipid (cholesterol and cholesterol ester) deposition in transduced cells [130,133]. This accumulation resulted from non-physiological over-expression of

LDLR mediated by the Ad vector, causing pathological intracellular accumulation of the lipid that could not be compensated by the hepatic cell metabolism [133,134].

The transient expression was not solely due to the episomal nature of Ad infection but also a result of host immune responses against adenoviral proteins [124,135,136]. Co-administration of an Ad vector encoding hLDLR driven by a CMV promoter, with a blocking antibody directed against CD154 (CD40 ligand) to suppress immune responses against the vector and foreign transgene product in LDLR *-/-* mice, resulted in long-term expression of LDLR and maintained cholesterol levels within and below the normal range for at least 92 days post vector delivery. The loss of hLDLR expression in non anti-CD154-treated mice also demonstrated the importance of the host immune response against vector and transgene products [137].

In direct response to these immunological reactions and vector cytotoxicity, helper dependent adenovirus (HD-Ad) vectors were developed, in which additional viral coding sequences were deleted [138]. This also increases the insert capacity of the vector to approximately 30 kb. Nomura and colleagues [139] compared the efficiency of monkey LDLR gene therapy with that of monkey very low density lipoprotein receptor (VLDLR) gene therapy, using HD-Ad. High cholesterol diet fed LDLR *-/-* mice were injected with a single intravenous application of high ( $1.5 \times 10^{13}$  vector particles (vp)/kg) and low ( $5 \times 10^{12}$  vp/kg) doses of HD-Ad. Throughout the 24-week experiment, plasma cholesterol of LDLR-treated mice was lower than that of VLDLR-treated mice. Anti-LDLR antibodies developed in 2 of 10 mice treated with high-dose HD-Ad-LDLR but in none (0/14) of the other treatment groups. The antibody titre in the high-dose experiments was significantly above background, but was three orders of magnitude lower than that seen following first generation Ad-LDLR treatment, indicating that the marked pro-inflammatory adenoviral protein expression following FG-Ad-LDLR gene transfer could have acted as an adjuvant that stimulated antibody production in these mice. Long-term efficacy of low-dose HD-Ad-LDLR injected into 12-week old LDLR *-/-* mice was tested and after 60 weeks, atherosclerosis lesions covered approximately 50% of the surface of aortas of control mice whereas aortas of treated mice were essentially lesion-free. The lipid lowering effect of HD-Ad-LDLR lasted at least 108 weeks (>2 years) when all control mice had died [139].

Despite the reported improvements achieved by HD-Ad, the cytotoxic effect resulting from immune response to high titre ( $3.8 \times 10^{13}$  IU/ml) administration of a 2<sup>nd</sup> generation adenoviral vector, which led to the unfortunate death of a patient in a non-FH clinical trial [125] stopped any further *in vivo* adenoviral vector delivery trials, pending improvement in vector design. In an

attempt to address this issue, Jacobs and colleagues investigated the use of a relatively low dose ( $5 \times 10^{10}$  particles) of second generation E1E3E4-deleted adenoviral vectors for transfer of the LDLR or VLDLR, under control of the hepatocyte-specific human  $\alpha_1$ -antitrypsin promoter and 4 copies of the human *apo E* enhancer, into C57BL/6 LDLR *-/-* mice [140]. Evaluation was performed for 30 weeks after vector delivery in male and female mice fed either standard chow or an atherogenic diet. Compared to control mice, AdLDLR and AdVLDLR persistently decreased plasma non-HDL cholesterol in both sexes and on both diets and potently inhibit development of atherosclerosis in the ascending aorta. The non-physiologically regulated over-expression of LDLR or VLDLR, transferred by E1E3E4-deleted adenoviral vectors, significantly reduces tissue cholesterol levels in myocardium, quadriceps muscle, and kidney and does not lead to pathological intracellular accumulation of cholesterol and cholesterol esters in hepatocytes. The effectiveness of the vectors and expression cassette used in this study is stressed by the fact that, using vector doses that are 2-7.5-fold lower compared to those in other studies [139,141], equivalent results were obtained in terms of lipid lowering and reduction of atherosclerosis [140]. However, immune response to the vector system to evaluate potential development of neutralizing antibody or immune rejection to the transgene and/or vector has not been shown.

Adenoviral based vectors still remain the most efficient class of vector in terms of delivering to and expressing their genetic cargo in the cells of most tissues. However, because of their transient expression characteristics, while they remain useful for proof of principle for gene therapy they are not the vector of choice for the treatment of inherited monogenic diseases but will probably find application in the treatment of cancer in which cellular toxicity and immunogenicity might even enhance their anti-tumour effects [142].

#### Adeno-associated virus vectors

Vectors based on adeno-associated virus (AAV), a small (20-25 nm) non-enveloped DNA virus (Figure 6) that is non-pathogenic and replication-defective, have a number of attributes that make them suitable for gene transfer to the liver for the treatment of FH. A single administration of recombinant AAV (rAAV) into the liver results in long-term transgenic protein expression without toxicity in a variety of animal models [143]. These pre-clinical studies have led to phase I/II trials of liver gene transfer for diseases such as haemophilia [144] for example, using AAV serotype 2, the first isolate to be characterised.

There are several current obstacles to AAV gene therapy that need to be addressed. Although AAV is not

known to cause human disease, 85% of the adult population is sero-positive for AAV capsid proteins [145] and wild type (wt) AAV2 is endemic to humans. Thus most of the patients that participated in clinical trials are likely to have had pre-existing immunity to the serotype employed, as a result of prior natural infection. Cytotoxic T-cells resulting from wt-AAV infection can eliminate transduced cells and anti-AAV2 antibodies are able to block or reduce gene transfer with rAAV2 vectors. These factors may have limited transgenic hFIX protein expression in a recent hemophilia B gene therapy trial [144]. Switching the capsid protein to other AAV serotypes that are less prevalent in humans can overcome these immunological problems [146]. There are several AAV serotypes available that may prove useful in the future for clinical translation.

Currently a high multiplicity of infection is needed to achieve therapeutic AAV mediated gene transfer. Efficient transduction of target cells is blocked at several levels during AAV cell infection and movement of the vector into the nucleus. The host gender appears to be an important consideration, since in mice exogenous androgens can increase stable hepatocyte gene transfer in females to levels observed in male mice [147]. Strategies such as blocking endosomal degradation of AAV with proteasome inhibitors significantly improve AAV transduction in mice [148,149]. Switching AAV capsid proteins to an alternative serotype such as AAV8 can also enhance uncoating of the vector and release of the genome [146].

The dsDNA genome of the AAV vector can persist as an episomal element in transduced cells for long periods of time in a variety of molecular forms, including circular monomers, linear monomers and linear concatemers by head to tail recombination of the ITRs. Integration of single and concatemeric genomes into the chromosomal DNA of the host cells occurs at low frequency [103]. Because the transgene is predominantly expressed from the episomal form, expression usually declines over time due to dilution in the replicating cells or degradation in non-dividing cells [105]. A recent study found that administration of Ad 10-20 weeks after AAV gene

transfer augmented AAV transgene expression two-fold by increasing the level of pro-viral mRNA [149] and this strategy may prove useful in clinical practice when transgenic protein expression levels fall.

Slow conversion of the virus single stranded (ss) to the double stranded (ds) DNA genome is another issue. After the AAV virus enters the nucleus, the virus single stranded DNA genome (ssDNA) is converted to a transcriptionally active double stranded DNA (dsDNA) [150]. Unless the conversion happens, ssDNA is lost rapidly after transduction, leading to a drop in transgenic protein expression. This rate-limiting conversion process can be circumvented by modifying the configuration of the provirus so that it is packaged as complementary dimer as opposed to the conventional ss [151]. This self-complementary (sc) AAV vector configuration has been shown to significantly improve gene transfer to the liver for human factor IX, achieving levels of stable transduction that are almost one order of magnitude higher than those achieved with an equivalent dose of comparable ssAAV [151,152]. Lowering the required dose of scAAV vector would be of benefit for safety considerations and for scaling up to clinical grade vector production. Modifying the promoter can alter the tissue-specific expression. Use of the liver-specific promoter, LP-1 for example in a self-complementary AAV2/3 vector driving the human factor IX (hFIX) protein, resulted in transgenic h(FIX) protein expression confined to the liver as detected by RT-PCR analysis [152]. This would be beneficial for FH gene therapy.

One of the earliest studies on AAV vectors for FH gene therapy found promising results. Reversal of hypercholesterolaemia was demonstrated in LDLR<sup>-/-</sup> mice fed with a high cholesterol diet after intraportal vascular injection of  $1 \times 10^{12}$  AAV-2 vector particles encoding the murine VLDLR driven by the CMV enhanced chicken  $\beta$ -actin promoter [153]. Western blot analysis and immunohistochemistry revealed high levels of VLDLR expression in approximately 2-5% of cells of liver harvested at 3 and 6 months after vector delivery with a low vector DNA copy number of 1 copy/cell. Serum cholesterol progressively declined after vector




Figure 6 Genomic organisation of the AAV and basic AAV vector design.

administration and by 6 months, the aortic atherosclerotic lesion area was reduced 33% compared with control mice injected with saline. Phenotypic correction was incomplete however, primarily due to immune activation by the vector products and low efficiency of gene transfer mediated by AAV-2.

Lebherz and colleagues [154] compared the efficiency of AAV-2, -7 and -8 serotype vectors carrying the human LDLRcDNA expressed from a liver specific promoter based on the human thyroxin binding globulin [155]. A vector dose of  $1 \times 10^{12}$  genome copies (gc) per mouse was injected into the portal veins of LDLR<sup>-/-</sup> mice that were fed a high-fat diet. Transduction efficiency was increased to 50 gc/cell and 10 gc/cell after treatment with an AAV-8 or AAV-7 vector respectively, compared with 2 gc/cell after administration of an AAV-2 vector. Animals receiving the AAV-LDLR serotype 7 and 8 achieved nearly complete normalization of serum lipids and failed to develop the severe atherosclerosis that characterized the untreated animals, with no apparent toxicity observed. Animals treated with the AAV-2 vector achieved partial lipid correction and only a modest improvement in atherosclerosis. Serotype 8 virus achieved stable transduction and expression of the transgene in up to 85% of the hepatocytes. These results are encouraging especially since no expression-terminating immune responses were detected [154]. There were similar findings in the apo-E mouse model of FH, where intravenous administration of AAV2/7- and AAV2/8-apoE vectors completely prevented atherosclerosis at 1 year [156].

Another approach using AAV vectors has been to try to counteract the development of atherosclerosis by gene transfer of interleukin-10 (IL10), an anti-inflammatory cytokine. Injection of AAV IL10 vector into the tail vein [157] of LDLR-knockout mice or into the tibial muscle [158] of apo-E deficient mice resulted in significantly lower levels of atherosclerosis.

More recently, a single intravenous injection of an AAV8 vector containing the mouse LDLR gene to a humanized mouse model of FH, the LDLR<sup>-/-</sup>-Apobec<sup>-/-</sup> mouse, was found to significantly reduce plasma cholesterol and non-HDL cholesterol levels in chow-fed animals at low doses. Treated mice realized an 87% regression of atherosclerotic lesions with substantial remodeling, after 3 months compared to baseline mice [159].

In summary, modifying the AAV vector system by altering the capsid (reviewed in [160]), including dsDNA and using a liver specific promoter may result in long term, stable and liver specific AAV mediated transgenic protein expression which may be suitable for FH gene therapy.

#### Lentivirus based vectors

Lentiviruses (LVs) are a complex sub-group of RVs responsible for a variety of immunological and neurological

diseases. Their biological and molecular and properties have been used to classify them as lenti-(slow) retroviruses. They can be subdivided into primate and non-primate viruses. The primate viruses are the human and simian immunodeficiency viruses (HIV and SIV), and the non-primate viruses include the feline and bovine immunodeficiency viruses, the caprine arthritis/encephalitis virus, the visna/maedi/ovine progressive pneumonia virus, and the equine infectious anaemia virus (EIAV) [107]. As for all RVs, the LV genome consists of a positive-strand polyadenylated RNA of about 10 kb and includes three genes; *gag*, *pol*, and *env* organised in the 5' to 3' orientation. Lentiviruses have additional unique small ORFs located between *pol* and *env* at the 3' terminus, which contain genes for regulatory proteins [107].

Interest in LVs as putative gene transfer systems is derived from the fact that they have the potential to integrate efficiently into the genome of dividing and non-dividing cells providing the possibility for lifetime correction with a single administration of vector [161,162]. Unlike the RV pre-integration complex, which can only reach the target cell nucleus when the nuclear membrane is disrupted during mitosis, the lentiviral PIC contains nuclear localisation signals, which mediate their transport through nuclear membrane pores into the nucleus during the cell interphase [163-165].

Although integration of linear DNA episome, provirus precursor, is generally regarded as the end point of gene transfer, two circular episomal types with intact viral coding regions are also generated by cellular proteins from retro- or lenti-viruses and their derived vectors [166]. The first type circularizes by non-homologous recombination of end-joining to form a circular episome with two adjacent LTRs (2-LTR circular episome) [167]. The second type circularizes by homologous recombination within the LTRs to form a circular episome with a single LTR (1-LTR circular episome) [168]. It has been estimated that approximately one-third of linear lentiviral DNA become circular episomal forms and can express proteins and remain metabolically stable and transcriptionally competent in target cells, although, the single LTR circular episomal forms are more prevalent than 2-LTR circles [166].

Using a LV backbone, two types of vector system can be produced and used for gene transfer, the first are integrated lentivirus based vectors (ILV) and the second are integration deficient lentiviral vectors (IDLV). Initial research on the development of lentivirus-based vectors has focused mainly on HIV-1 derived integrated LV vectors as prototype. This is facilitated by the abundance of knowledge that has been accumulated on this virus since its recognition in 1984 as the causative agent of acquired immuno-deficiency syndrome. Like other virally derived vectors, the initial problem to overcome



is to maintain viral infectivity but to render the virus replication deficient [161,162]. The LV based vector design is very similar to that of the three-plasmid co-transfection RV system based on MoMLV, described above. In addition, the emergence of a host immune response against lentiviral vectors has not been shown in most of the preclinical studies [169-173].

Due to the increased concern of insertional mutagenesis (IM) caused by integrating retro- and lentivirus based vectors (as will be discussed later), IDLVs has been thought of as a logical alternative to alleviate the risk of IM. IDLV particles can be generated by the use of integrase mutations that specifically prevent proviral integration resulting in the generation of increased levels of circular vector episomes in transduced cells, but not to compromise its other functions. Because these lentiviral circular episomes lack replication signals, they are gradually lost by dilution in the transduced actively dividing cells, but are stable for several months in transduced quiescent cells [174-176]. Compared to integrating lenti-vectors, IDLVs have a significantly reduced risk of causing IM, a lesser risk of generating RCRs, a reduced risk of transgene silencing [177], and also extremely low levels of integration (residual background integration frequencies of IDLVs in cultured cells through non-integrase pathways are within the range described for plasmid transfection (reviewed in [166,178])).

Recent studies using IDLVs have demonstrated effective gene transfer in the eye [176], brain [174,179], muscle [180], and to a lesser extent in the liver [181], albeit at lower expression levels than with integrating vectors. In addition to gene transfer, IDLVs are also proficient vectors for gene repair and can be converted into stable, replicating circular episomes. These properties, combined with their highly reduced risk of causing IM, have led to increased interest on IDLVs for gene transfer and therapy. Because of the possibility of mobilization by superinfection with replication competent viruses, it has been suggested that future IDL-based vectors should carry *att* mutations in addition to those in the integrase to minimize integration in the event of vector mobilization (reviewed in [166,178])). Long-term evidence for lack of genomic integration beyond residual levels warrants future investigation. To date, IDLVs have not been used for LDLR gene transfer and FH gene therapy.

Many labs including ours [182] experienced difficulties to produce infectious ILVs for transfer and expression of human LDLR under control of a ubiquitous promoter. However, based on the utilisation of a previously characterised liver specific promoter (LSP) [183], Kankkonen and colleagues were able to demonstrate for the first time the successful construction and production of high titre ( $1 \times 10^9$  IU) third-generation HIV-1 based lentiviral vectors encoding rabbit LDLR. LSP-driven transgene

expression was detected after *in vitro* gene transfer into human hepatoma (HepG2) cells, but not after transfer into HeLa cells, HEK 293 cells, or WHHL rabbit skin fibroblasts [183,184]. *In vivo* injection of  $1 \times 10^9$  infectious virus particles into the portal vein of WHHL rabbits resulted in liver-specific expression of the LDLR and clinical chemistry and histological analyses showed normal liver function and morphology during the 2-year follow-up without safety issues. This vector dose resulted in low transduction efficiency (<0.01%) but demonstrated on average a  $147 \pm 7\%$  decrease in serum cholesterol levels during the first 4 weeks, a  $44 \pm 8\%$  decrease at 1 year and a  $34 \pm 10\%$  decrease at the 2-year time point, compared to the control rabbits infected with HIV-green fluorescent protein. During this period, 70% of the rabbits treated with the liver specific lentiviral LDLR vector demonstrated a positive treatment effect with lowered plasma cholesterol levels ( $25 \pm 8\%$ ). However, the detailed pattern of bio-distribution after HIV-vector mediated gene transfer, to evaluate potential risks for possible IM and germ-line transmission, has not been investigated.

#### Vector safety in gene therapy

The integration of RV and LV into the genome during gene therapy has caused concern because of the potential for vector-related deleterious side effects on the host. This is, in part, due to the fact that vector insertion occurs in a semi-random manner into actively transcribed genes. For RV vectors insertion preference is for gene promoter regions [185-188] whereas LVs appear to target the transcription unit of the gene [189,190] and therefore are believed less likely to cause effects on host gene expression following integration [191-194]. Genotoxicity by RV vectors associated with insertional mutagenesis (IM) has been studied for several years and the theoretical calculated estimates of mutagenesis at a haploid locus are supported by *in vitro* studies using model systems based on mutagenesis of the *hprt* locus or genes that control promotion of growth factor independence at frequencies between  $10^{-5}$ - $10^{-7}$  per provirus insertion [191,192]. Hence, the likelihood of adverse events caused by RV integration following therapeutic application was considered remote. Unfortunately and unexpectedly, however, development of clonal dominance has been observed in two patient trials that is attributed to RV mediated IM [86,195-199].

In an *ex vivo* trial carried out in France that used patients' own haematopoietic stem cells for transplantation after retroviral transduction to correct X-linked severe combined immuno-deficiency (X-SCID), clonally dominant clones have developed into leukaemias in 4 of these patients [85,86,196]. This also occurred in one patient in a British X-SCID trial [198]. In 4 of these

cases integration by MoMLV is believed to have caused IM by inserting near the *LMO2* gene [196,198]. In addition, insertions have been found in both *BMI1* and *CCND2* proto-oncogenes [196,198]. Although 5 out of the 20 patients that enrolled in the French and British trials have developed leukaemia it is difficult to understand clearly the events leading to this disease because of existing genetic abnormalities in the patients' cells that have also been identified. These include chromosomal translocations, gain-of-function mutations activating *NOTCH1*, deletion of tumour suppressor gene *CDKN2A*, 6q interstitial losses, and *SIL-TALI* rearrangement [196,198].

In a more recent trial for chronic granulomatous disease (CGD) clonal dominance has also been attributed to retrovirus mediated IM 5 month after vector delivery in 2 patients [199]. Vector integrations activated the zinc finger transcription factor homolog's *MDS1/EVI1*, *PRDM16* or *SETBP1* raising concerns that this could eventually cause tumourgenesis. The first affected patient died 2.5 years after vector delivery as a result of a severe sepsis and the second patient has undergone allogeneic transplant [199,200].

In response to these findings, *ex-vivo* and *in vitro* models have been developed in order to examine RV and LV genotoxicity using haematopoietic cells. *Ex vivo* gene therapy using stem cells is considered a more controllable way of introducing genetic modification to the host than by direct systemic vector administration *in vivo* [201-205]. These models have confirmed that insertion of RV, and to a lesser extent SIN-RV and LV can contribute to leukaemic development [85,201-206]. Factors implicated in this process include the integrated vector copy number, integration sites, vector configuration and even the transgene carried by the vector [85,201-206]. Most recently, host cell transcription, in combination with the mutational potential of the vector, has been shown to be involved in the emergence of clonal dominance [206,207].

In our laboratory we have developed a model more suited to gene therapy for FH where vectors may be delivered directly *in vivo*. In this model vector application *in utero* is performed via the fetal mouse circulation that results in gene transfer to most organs, although the liver is mainly transduced [208]. We found that using a primate HIV-1 based vector carrying the human factor IX (hFIX) gene to correct haemophilia in a knockout mouse model of this disease comprehensive cure was achieved without adverse effects, however, the use of a non-primate EIAV vector driving hFIX gene expression led to a high frequency of liver tumours in these mice [209]. This model is still under development, and we have also obtained similar results with the non-primate feline immuno-deficiency (FIV) vector (Themis

*et al.* unpublished data). Most importantly in these tumours, we find insertions within genes assigned as candidate genes involved in cancer development (within a 100 kb integration site window - the theoretical distance by which vector insertion is believed to influence expression of a gene carrying the integrated vector). More than 50% of these genes are registered in the Mouse Retroviral Tagged Cancer Gene Database (RTCGD) [210]. Furthermore, many genes carrying insertions have altered gene expression suggestive of IM by the non-primate LV. Hence, using *in utero* gene delivery where genes are in a highly active transcription state, we are able to sensitively detect adverse effects caused by vector integration.

The current models for vector associated genotoxicity all rely on the use of rodent cells as a measure of IM. As these cells are more predisposed to tumour development than human cells, each must be viewed with caution as reliable predictors for mutagenesis occurring in the clinic. The finding of vector genotoxicity in the clinic has, however, revived the use of models of genotoxicity to obtain useful information regarding safe vector design. They may also help to elucidate possible mechanisms relating to IM. In summary, the importance of genotoxicity assays to understand the cause and measure the risk of adverse effects by gene therapy of FH and indeed the treatment of any disease with these vectors cannot be overstated. With the current genotoxicity assays in place we are becoming more confident that gene therapy to FH homozygotes will be possible with minimal side effects.

## Conclusion

Several novel therapies have been developed recently to lower LDL-C in homozygous and heterozygous FH patients [57-65,211]. However, their major drawback is the need for life-long repeated administration in a similar manner to conventional pharmacological drugs. The advantage of gene therapeutic intervention over other therapeutic regimes is the potential for lifetime correction with a single vector administration. Yet, this goal still needs to be achieved. Despite the considerable progress, made in optimising the two most commonly used gene therapy vector-groups based on retro- and adenoviruses, neither vector has been found to be ideal for *in vivo* and/or *ex vivo* gene transfer. Vectors derived from AAV and LVs are very promising. However, the oncogenesis risk from semi-random integration into actively transcribing genes of the host by LVs [189,212,213], possible germline transmission [214] and some immunological reaction after AAV gene transfer in the human haemophilia-B trials [144,215] are critical drawbacks that require further vector development and improvement.

In addition to the LDLR gene augmentation approach, the successful use of the VLDLR as an effective surrogate lipoprotein receptor gene [139-141,153,216,217] for the complementation of mutated LDLR function in homozygote FH patients would also open an alternative therapeutic avenue, since it would avoid the immune problem in patients with no natural LDLR. Despite the fact that most of the pre-clinical and clinical studies were aimed at treatment of the homozygous form of FH, a minority of heterozygous FH patients, who are refractory to existing pharmacological therapy, are also possible targets. Therefore, once a safe and efficient transfer vector is developed and shown to be effective in homozygous FH, its application might be extended to severe heterozygous FH as well. Clearly there is also an urgent demand for safe and efficient vectors that would integrate into the host genome and provide long-term appropriate gene expression for *in vivo* and/or *ex vivo* gene therapy of FH and many other human diseases.

Future work will generally focus on making gene transfer vectors safer by improving their immunogenic, integration, expression and targeting profile. Reducing the inherent oncogenic danger of integrating vectors by engineering conditional suicide genes into the vector backbone to provide a self-destructive mechanism in case of oncogenesis or by targeting their integration into specific pre-defined benign genomic sites, i.e. by zinc-finger nuclease technology, may help achieving this goal [218]. In combinations with the above strategies, the use of *ex vivo* transduction to reduce vector spread can also improve the safety outcome, particularly, if autologous or induced pluripotent stem cells are the target. The application of viral or non-viral, integrating or non-integrating vectors for long term persistence in stem cells with self renewal and differentiation capacities will also be important perspectives for gene-based stem cell therapy.

### Competing interest Disclosure

The authors declare that they have no competing interests.

### Acknowledgements

This work was supported by joint grants from the King Abdulaziz City for Science and Technology (KACST), the Saudi Basic Industries Corporation and Umm-Alqura University, Kingdom of Saudi Arabia. AD is receiving funding from the Department of Health's NIHR Biomedical Research Centres funding scheme.

### Author details

<sup>1</sup>Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Al-Abedia Campus, P. O. Box 715, Makkah 21955, Saudi Arabia. <sup>2</sup>Gene Therapy Research Group, Department of Molecular and Cell Medicine, Sir Alexander Fleming Building, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. <sup>3</sup>Department of Haematology, Haemophilia Centre and Haemostasis Unit, Royal Free and University College Medical School, London NW3 2PF, UK. <sup>4</sup>Prenatal Cell and Gene Therapy Group,

Institute for Women's Health, University College London, 86 - 96 Chenies Mews, London, WC1E 6HX, UK. <sup>5</sup>Gene Therapy and Genotoxicity Research Group, Brunel University, Heinz Wolff Building, Uxbridge, Middlesex, West London UB8 3PH, UK.

### Authors' contributions

FAA is responsible for conceiving this work and writing the manuscript. CC, SW, ALD, RH, and MT participated in the drafting of this manuscript. All authors read and approved the final manuscript.

### Author's information

F. A. A. is an Assistant Professor of Genetics and Molecular Medicine, Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Al-Abedia Campus, Makkah 21955, Saudi Arabia. C. C. is an Emeritus Professor and Former Leader, Gene Therapy Research Group, Department of Molecular and Cell Medicine, Sir Alexander Fleming Building, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. S. W. is a Lecturer and Group Leader, Prenatal Gene Therapy Research Group, Department of Haematology, Haemophilia Centre and Haemostasis Unit, Royal Free and University College Medical School, London NW3 2PF, UK. R. H. is a Research Fellow and Gene Therapy Group Leader in the Section of Molecular Medicine in the Sir Alexander Fleming Building, NHLI, Imperial College London, London SW7 2AZ, UK. A. L. D. is a Senior Lecturer and Honorary Consultant in Obstetrics and Maternal/Fetal Medicine, and leads the Prenatal Cell and Gene Therapy Group, Institute for Women's Health, University College London and UCLH, 86-96 Chenies Mews, London, WC1E 6HX, UK. M. T. is a Lecturer and Group Leader, Gene Therapy and Genotoxicity Research Group, Brunel University, Heinz Wolff Building, Uxbridge, Middlesex, West London UB8 3PH, UK.

Received: 13 May 2010 Accepted: 13 December 2010  
Published: 13 December 2010

### References

1. Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. *Science (New York, NY)* 1986, **232**(4746):34-47.
2. Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE: Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. *Annals of human genetics* 2008, **72**(Pt 4):485-498.
3. The Leiden Open (source) Variation Database (LOVD). [http://www.ucl.ac.uk/ldlr/Current/].
4. Austin MAHC, Zimmern RL, Humphries SE: Familial hypercholesterolemia and coronary heart disease: a HuGE association review. *Am J Epidemiol* 2004, **160**:421-429.
5. Vega GL, Grundy SM: In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. *The Journal of clinical investigation* 1986, **78**(5):1410-1414.
6. Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ: Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. *Proceedings of the National Academy of Sciences of the United States of America* 1989, **86**(2):587-591.
7. Austin MAHC, Zimmern RL, Humphries SE: Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. *Am J Epidemiol* 2004, **160**:407-420.
8. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nature genetics* 2003, **34**(2):154-156.
9. Soutar AK, Naoumova RP, Traub LM: Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. *Arteriosclerosis, thrombosis, and vascular biology* 2003, **23**(11):1963-1970.
10. Soutar AK, Naoumova RP: Mechanisms of disease: genetic causes of familial hypercholesterolemia. *Nature clinical practice* 2007, **4**(4):214-225.
11. Kwitterovich PO Jr, Bachorik PS, Smith HH, McKusick VA, Connor WE, Teng B, Sniderman AD: Hyperapobetalipoproteinaemia in two families with xanthomas and phytosterolaemia. *Lancet* 1981, **1**(8218):466-469.

12. Yamamoto A, Kamiya T, Yamamura T, Yokoyama S, Horiguchi Y, Funahashi T, Kawaguchi A, Miyake Y, Beppu S, Ishikawa K: **Clinical features of familial hypercholesterolemia.** *Arteriosclerosis* 1989, **9**(1 Suppl):166-74.
13. Goldstein JL, Brown MS: **Familial hypercholesterolemia: a genetic receptor disease.** *Hosp Pract (Off Ed)* 1985, **20**(11):35-41, 45-36.
14. Brochier ML, Arwidson P: **Coronary heart disease risk factors in women.** *European heart journal* 1998, **19**(Suppl A):A45-52.
15. Heath KE, Gahan M, Whittall RA, Humphries SE: **Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis.** *Atherosclerosis* 2001, **154**(1):243-246.
16. Seftel HC, Baker SG, Sandler MP, Forman MB, Joffe BI, Mendelsohn D, Jenkins T, Miemy CJ: **A host of hypercholesterolaemic homozygotes in South Africa.** *Br Med J* 1980, **281**(6241):633-636.
17. Steyn K, Weight MJ, Dando BR, Christopher KJ, Rossouw JE: **The use of low density lipoprotein receptor activity of lymphocytes to determine the prevalence of familial hypercholesterolaemia in a rural South African community.** *J Med Genet* 1989, **26**(1):32-36.
18. Marks D, Thorogood M, Neil HA, Humphries SE: **A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.** *Atherosclerosis* 2003, **168**(1):1-14.
19. Marenah C: **Lipid metabolism, hyper- and hypolipidaemias and atherosclerosis.** In *Clinical biochemistry: metabolic and clinical aspects. Volume 35.* Edited by: Marshall W, Bangert S. Edinburgh: Churchill Livingstone; 1995:621-640.
20. Stanley KK, Kocher HP, Luzio JP, Jackson P, Tschopp J: **The sequence and topology of human complement component C9.** *Embo J* 1985, **4**(2):375-382.
21. Russell DW, Schneider WJ, Yamamoto T, Luskey KL, Brown MS, Goldstein JL: **Domain map of the LDL receptor: sequence homology with the epidermal growth factor precursor.** *Cell* 1984, **37**(2):577-585.
22. Goldstein JL, Brown MS, Anderson RG, Russell DW, Schneider WJ: **Receptor-mediated endocytosis: concepts emerging from the LDL receptor system.** *Annu Rev Cell Biol* 1985, **1**:1-39.
23. Sudhof TC, Goldstein JL, Brown MS, Russell DW: **The LDL receptor gene: a mosaic of exons shared with different proteins.** *Science* 1985, **228**(4701):815-822.
24. Sudhof TC, Russell DW, Goldstein JL, Brown MS, Sanchez-Pescador R, Bell GI: **Cassette of eight exons shared by genes for LDL receptor and EGF precursor.** *Science* 1985, **228**(4701):893-895.
25. Goldstein JL, Hobbs HH, Brown MS: **Familial hypercholesterolaemia.** In *The Metabolic and Molecular Basis of Inherited Diseases.* Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B. New York: McGraw-Hill; 2001:2863-2913.
26. Sudhof TC, Van der Westhuyzen DR, Goldstein JL, Brown MS, Russell DW: **Three direct repeats and a TATA-like sequence are required for regulated expression of the human low density lipoprotein receptor gene.** *The Journal of biological chemistry* 1987, **262**(22):10773-10779.
27. Fielding CJ, Fielding PE: **Intracellular cholesterol transport.** *Journal of lipid research* 1997, **38**(8):1503-1521.
28. Knopp RH, Superko HR, Davidson M, Insull W, Dujovne CA, Kwiterovich PO, Zavoral JH, Graham K, O'Connor RR, Edelman DA: **Long-term blood cholesterol-lowering effects of a dietary fiber supplement.** *Am J Prev Med* 1999, **17**(1):18-23.
29. Knopp RH, Walden CE, Retzlaff BM, McCann BS, Dowdy AA, Albers JJ, Gey GO, Cooper MN: **Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study.** *Jama* 1997, **278**(18):1509-1515.
30. Walden CE, Retzlaff BM, Buck BL, McCann BS, Knopp RH: **Lipoprotein lipid response to the National Cholesterol Education Program step II diet by hypercholesterolemic and combined hyperlipidemic women and men.** *Arteriosclerosis, thrombosis, and vascular biology* 1997, **17**(2):375-382.
31. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: **Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.** *Circulation* 2004, **110**(2):227-239.
32. Blumenthal RS: **Statins: effective antiatherosclerotic therapy.** *Am Heart J* 2000, **139**(4):577-583.
33. Tsuyuki RT, Bungard TJ: **Poor adherence with hypolipidemic drugs: a lost opportunity.** *Pharmacotherapy* 2001, **21**(5):576-582.
34. Davidson MH: **Reducing residual risk for patients on statin therapy: the potential role of combination therapy.** *The American journal of cardiology* 2005, **96**(9A):3K-13K, discussion 34K-35K.
35. Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, Isaacsohn J, Toth P, Burke SK: **Colesevelam hydrochloride (cholestugel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.** *Arch Intern Med* 1999, **159**(16):1893-1900.
36. Berge KG, Canner PL: **Coronary drug project: experience with niacin.** *Coronary Drug Project Research Group. European journal of clinical pharmacology* 1991, **40**(Suppl 1):S49-51.
37. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: **Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.** *The New England journal of medicine* 1999, **341**(6):410-418.
38. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Pevovskaya I, von Bergmann K: **Inhibition of intestinal cholesterol absorption by ezetimibe in humans.** *Circulation* 2002, **106**(15):1943-1948.
39. Stein EA: **Management of dyslipidemia in the high-risk patient.** *Am Heart J* 2002, **144**(6 Suppl):S43-50.
40. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP: **Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.** *The American journal of cardiology* 2002, **90**(10):1092-1097.
41. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP: **Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.** *European heart journal* 2003, **24**(8):729-741.
42. Berneis K, Rizzo M, Berthold HK, Spinaz GA, Krone W, Gouni-Berthold I: **Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial.** *European heart journal* 2010, **31**(13):1633-1639.
43. Dembowski E, Davidson MH: **Statin and ezetimibe combination therapy in cardiovascular disease.** *Current opinion in endocrinology, diabetes, and obesity* 2009, **16**(2):183-188.
44. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK: **Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.** *Atherosclerosis* 2001, **158**(2):407-416.
45. Illingworth DR: **New horizons in combination drug therapy for hypercholesterolemia.** *Cardiology* 1989, **76**(Suppl 1):83-94, discussion 94-100.
46. Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tereshakovec AM: **Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome.** *Diab Vasc Dis Res* 2006, **3**(2):93-102.
47. Gagne C, Gaudet D, Bruckert E: **Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.** *Circulation* 2002, **105**(21):2469-2475.
48. Bilheimer DW, Goldstein JL, Grundy SM, Brown MS: **Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia.** *J Clin Invest* 1975, **56**(6):1420-1430.
49. Keller C: **LDL-apheresis: results of longterm treatment and vascular outcome.** *Atherosclerosis* 1991, **86**(1):1-8.
50. Mora C, Teruel JL, Navarro JF: **Low-density lipoprotein apheresis in homozygous familial hypercholesterolemia.** *The American journal of cardiology* 2001, **88**(2):202-203.
51. Teruel JL, Lasuncion MA, Navarro JF, Carrero P, Ortuno J: **Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption.** *Metabolism* 1995, **44**(7):929-933.
52. Thompson GR: **Recommendations for the use of LDL apheresis.** *Atherosclerosis* 2008, **198**(2):247-255.
53. Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, Mandy P, Marais AD, Matthews S, Neuwirth C, Pottle A, le Roux C, Scullard D, Tyler C, Watkins S: **Efficacy criteria and cholesterol targets for LDL apheresis.** *Atherosclerosis* 2010, **208**(2):317-321.

54. Bilheimer DW, Goldstein JL, Grundy SM, Starzl TE, Brown MS: **Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia.** *The New England journal of medicine* 1984, **311**(26):1658-1664.
55. Starzl TE, Bilheimer DW, Bahnson HT, Shaw BW Jr, Hardesty RL, Griffith BP, Iwatsuki S, Zitelli BJ, Gartner JC Jr, Malatack JJ, Urbach AH: **Heart-liver transplantation in a patient with familial hypercholesterolaemia.** *Lancet* 1984, **1**(8391):1382-1383.
56. Hoeg JM, Starzl TE, Brewer HB Jr: **Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia.** *Am J Cardiol* 1987, **59**(6):705-707.
57. El Harchaoui K, Akdim F, Stroes ES, Trip MD, Kastelein JJ: **Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins.** *Am J Cardiovasc Drugs* 2008, **8**(4):233-242.
58. Amin D, Rutledge RZ, Needle SN, Galczenski HF, Neuenschwander K, Scotese AC, Maguire MP, Bush RC, Hele DJ, Bilder GE, Perrone MH: **RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.** *The Journal of pharmacology and experimental therapeutics* 1997, **281**(2):746-752.
59. Aggarwal D, West KL, Zern TL, Shrestha S, Vergara-Jimenez M, Fernandez ML: **JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs.** *BMC cardiovascular disorders* 2005, **5**:30.
60. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ: **Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.** *The New England journal of medicine* 2007, **356**(2):148-156.
61. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, Gamba-Vitalo C, Hadwiger P, Jayaraman M, John M, Jayaprakash KN, Maier M, Nechev L, Rajeev KG, Read T, Rohl I, Soutschek J, Tan P, Wong J, Wang G, Zimmermann T, de Fougerolles A, Vornlocher HP, Langer R, Anderson DG, Manoharan M, et al: **Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.** *Proceedings of the National Academy of Sciences of the United States of America* 2008, **105**(33):11915-11920.
62. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Kotliansky V, Limmer S, Manoharan M, Vornlocher HP: **Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.** *Nature* 2004, **432**(7014):173-178.
63. Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, Orum H, Elmen J, Seidah NG, Straarup EM: **A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.** *PLoS one* 2010, **5**(5):e10682.
64. Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, Witztum JL, Tsimikas S: **Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.** *Circulation* 2008, **118**(7):743-753.
65. Raal FJ, Santos RD, Blom DJ, Marais AD, Chang MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST: **Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.** *Lancet* 2010, **375**(9719):998-1006.
66. **The Medical News.** [http://www.news-medical.net/news/20100805/Genzyme-Isis-announce-results-of-two-mipomersen-phase-3-studies.aspx].
67. **ClinicalTrials.gov identifier: NCT00281008.** [http://clinicaltrials.gov/ct2/show/NCT00281008?term=NCT00281008&rank=1].
68. **ClinicalTrials.gov identifier: NCT00607373.** [http://clinicaltrials.gov/ct2/results?term=NCT00607373].
69. **ClinicalTrials.gov identifier: NCT00694109.** [http://clinicaltrials.gov/ct2/show/NCT00694109].
70. **ClinicalTrials.gov identifier: NCT00706849.** [http://clinicaltrials.gov/ct2/show/study/NCT00706849].
71. Raper SE, Wilson JM: **Gene therapy for human liver disease.** *Prog Liver Dis* 1995, **13**:201-230.
72. Kormis KK, Wu GY: **Prospects of therapy of liver diseases with foreign genes.** *Semin Liver Dis* 1995, **15**(3):257-267.
73. Cichon G, Strauss M: **The liver as a target for gene therapy.** In *Concept in gene therapy. Volume 13.* Edited by: Strauss M, Barranger J. Berlin: Walter de Gruyter; 1997:267-281.
74. Tietge UJ, Cichon G, Buttner C, Genschel J, Heeren J, Gielow P, Grewe N, Dogar M, Beisiegel U, Manns MP, Lochs H, Burchert W, Schmidt HH: **A sensitive noninvasive method for monitoring successful liver-directed gene transfer of the low-density lipoprotein receptor in Watanabe hyperlipidemic rabbits in vivo.** *Gene Ther* 2004, **11**(7):574-580.
75. Watanabe Y, Ito T, Shiomi M: **The effect of selective breeding on the development of coronary atherosclerosis in WHHL rabbits. An animal model for familial hypercholesterolemia.** *Atherosclerosis* 1985, **56**(1):71-79.
76. Scanu AM, Khalil A, Neven L, Tidore M, Dawson G, Pfaffinger D, Jackson E, Carey KD, McGill HC, Fless GM: **Genetically determined hypercholesterolemia in a rhesus monkey family due to a deficiency of the LDL receptor.** *J Lipid Res* 1988, **29**(12):1671-1681.
77. Shibashi S, Goldstein JL, Brown MS, Herz J, Burns DK: **Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice.** *The Journal of clinical investigation* 1994, **93**(5):1885-1893.
78. Yamamoto T, Bishop RW, Brown MS, Goldstein JL, Russell DW: **Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit.** *Science (New York, NY)* 1986, **232**(4755):1230-1237.
79. Schneider WJ, Brown MS, Goldstein JL: **Kinetic defects in the processing of the low density lipoprotein receptor in fibroblasts from WHHL rabbits and a family with familial hypercholesterolemia.** *Molecular biology & medicine* 1983, **1**(3):353-367.
80. Shiomi M, Ito T: **The Watanabe heritable hyperlipidemic (WHHL) rabbit, its characteristics and history of development: a tribute to the late Dr. Yoshio Watanabe.** *Atherosclerosis* 2009, **207**(1):1-7.
81. Nakamura M, Taniguchi S, Ishida BY, Kobayashi K, Chan L: **Phenotype interaction of apobec-1 and CETP, LDLR, and apoE gene expression in mice: role of apoB mRNA editing in lipoprotein phenotype expression.** *Arteriosclerosis, thrombosis, and vascular biology* 1998, **18**(5):747-755.
82. Agellon LB, Walsh A, Hayek T, Moulin P, Jiang XC, Shelanski SA, Breslow JL, Tall AR: **Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice.** *The Journal of biological chemistry* 1991, **266**(17):10796-10801.
83. Wivel LA, Wilson JM: **Methods of gene delivery.** *Hematol Oncol Clin North Am* 1998, **12**(3):483-501.
84. Weatherall DJ: **Scope and limitations of gene therapy.** *Br Med Bull* 1995, **51**(1):1-11.
85. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A: **A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.** *The New England journal of medicine* 2003, **348**(3):255-256.
86. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JJ, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, et al: **LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.** *Science (New York, NY)* 2003, **302**(5644):415-419.
87. Schmidt-Wolf GD, Schmidt-Wolf IG: **Non-viral and hybrid vectors in human gene therapy: an update.** *Trends Mol Med* 2003, **9**(2):67-72.
88. Audouy SA, de Leij LF, Hoekstra D, Molema G: **In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.** *Pharm Res* 2002, **19**(11):1599-1605.
89. Mahato RI, Kawabata K, Nomura T, Takakura Y, Hashida M: **Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes.** *J Pharm Sci* 1995, **84**(11):1267-1271.
90. Liu F, Song Y, Liu D: **Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.** *Gene therapy* 1999, **6**(7):1258-1266.

91. Razzini G, Parise F, Calebiro D, Battini R, Bagni B, Corazzari T, Tarugi P, Angelelli C, Molinari S, Falqui L, Ferrari S: **Low-density lipoprotein (LDL) receptor/transferrin fusion protein: in vivo production and functional evaluation as a potential therapeutic tool for lowering plasma LDL cholesterol.** *Human gene therapy* 2004, **15**(6):533-541.
92. Krieger M, Brown MS, Goldstein JL: **Isolation of Chinese hamster cell mutants defective in the receptor-mediated endocytosis of low density lipoprotein.** *J Mol Biol* 1981, **150**(2):167-184.
93. Wade-Martins R, Saeki Y, Chiocca EA: **Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells.** *Mol Ther* 2003, **7**(5 Pt 1):604-612.
94. Lufino MM, Manservigi R, Wade-Martins R: **An S/MAR-based infectious episomal genomic DNA expression vector provides long-term regulated functional complementation of LDLR deficiency.** *Nucleic acids research* 2007, **35**(15):e98.
95. Hibbitt OC, Harbottle RP, Waddington SN, Bursill CA, Coutelle C, Channon KM, Wade-Martins R: **Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection.** *The journal of gene medicine* 2007, **9**(6):488-497.
96. Hibbitt OC, McNeil E, Lufino MM, Seymour L, Channon K, Wade-Martins R: **Long-term physiologically regulated expression of the low-density lipoprotein receptor in vivo using genomic DNA mini-gene constructs.** *Mol Ther* 2010, **18**(2):317-326.
97. Akdim F, Stroes ES, Kastelein JJ: **Antisense apolipoprotein B therapy: where do we stand?** *Current opinion in lipidology* 2007, **18**(4):397-400.
98. Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, Jukema JW, Flaim JD, Su J, Yu R, Baker BF, Wedel MK, Kastelein JJ: **Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.** *Journal of the American College of Cardiology* 2010, **55**(15):1611-1618.
99. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ: **An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.** *Journal of lipid research* 2005, **46**(5):872-884.
100. Ito MK: **ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?** *The Annals of pharmacotherapy* 2007, **41**(10):1669-1678.
101. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM: **Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.** *Circulation* 2006, **114**(16):1729-1735.
102. Tavidou A, Manolopoulos VG: **Novel molecules targeting dyslipidemia and atherosclerosis.** *Current medicinal chemistry* 2008, **15**(8):792-802.
103. Verma IM, Somia N: **Gene therapy – promises, problems and prospects.** *Nature* 1997, **389**(6648):239-242.
104. Chen WY, Bailey EC, McCune SL, Dong JY, Townes TM: **Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase.** *Proceedings of the National Academy of Sciences of the United States of America* 1997, **94**(11):5798-5803.
105. Thomas CE, Ehrhardt A, Kay MA: **Progress and problems with the use of viral vectors for gene therapy.** *Nat Rev Genet* 2003, **4**(5):346-358.
106. Dorigo O, Gil JS, Gallaher SD, Tan BT, Castro MG, Lowenstein PR, Calos MP, Berk AJ: **Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells.** *J Virol* 2004, **78**(12):6556-6566.
107. Coffin J, Hughes SH, Varmus HE: **Retroviruses.** New York: Cold Spring Harbor Laboratory Press; First 1997.
108. Mann R, Mulligan RC, Baltimore D: **Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.** *Cell* 1983, **33**(1):153-159.
109. Gunzburg WH, Salmons B: **Retroviral vectors.** In *Gene Therapy. Volume 1..* First edition. Edited by: Lemoine NR, Cooper DN. Oxford: BIOS Scientific Publishers Limited; 1996:72-102.
110. Davis JL, Witt RM, Gross PR, Hokanson CA, Jungles S, Cohen LK, Danos O, Spratt SK: **Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies.** *Human gene therapy* 1997, **8**(12):1459-1467.
111. DePolo NJ, Harkleroad CE, Bodner M, Watt AT, Anderson CG, Greengard JS, Murthy KK, Dubensky TW Jr, Jolly DJ: **The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent.** *J Virol* 1999, **73**(8):6708-6714.
112. Danos O, Mulligan RC: **Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges.** *Proc Natl Acad Sci USA* 1988, **85**(17):6460-6464.
113. Burns JC, T F, Driever W, Burrascano M, Yee JK: **Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells.** *Proc Natl Acad Sci USA* 1993, **1**:90(17):8033-8037.
114. Bender MA, Palmer TD, Gelinas RE, Miller AD: **Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region.** *J Virol* 1987, **61**(5):1639-1646.
115. Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U, Anderson WF, Wagner EF, Gilboa E: **Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells.** *Proc Natl Acad Sci USA* 1986, **83**(10):3194-3198.
116. Chowdhury JR, Grossman M, Gupta S, Chowdhury NR, Baker JR Jr, Wilson JM: **Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits.** *Science (New York, NY)* 1991, **254**(5039):1802-1805.
117. Grossman M, Raper SE, Wilson JM: **Transplantation of genetically modified autologous hepatocytes into nonhuman primates: feasibility and short-term toxicity.** *Human gene therapy* 1992, **3**(5):501-510.
118. Grossman M, Wilson JM, Raper SE: **A novel approach for introducing hepatocytes into the portal circulation.** *J Lab Clin Med* 1993, **121**(3):472-478.
119. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D, Lupien PJ, Wilson JM: **Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia.** *Nat Genet* 1994, **6**(4):335-341.
120. Brown MS, Goldstein JL, Havel RJ, Steinberg D: **Gene therapy for cholesterol.** *Nature genetics* 1994, **7**(3):349-350.
121. Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJ, Stein EA, Lupien PJ, Brewer HB Jr, Raper SE, Wilson JM: **A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia.** *Nat Med* 1995, **1**(11):1148-1154.
122. Shenk T: **Adenoviridae, The viruses and their replication.** In *Fields Virology. Volume 2..* 4 edition. Edited by: Fields B, Knipe D, Howley P. Philadelphia: Lippincott-William and Wilkins; 1999:2265-2300.
123. Kozarsky K, Grossman M, Wilson JM: **Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia.** *Somatic cell and molecular genetics* 1993, **19**(5):449-458.
124. Kozarsky KF, Jooss K, Donahee M, Strauss JF, Wilson JM: **Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene.** *Nat Genet* 1996, **13**(1):54-62.
125. Lehrman S: **Virus treatment questioned after gene therapy death.** *Nature* 1999, **401**(6753):517-518.
126. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: **Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5.** *Science* 1997, **275**(5304):1320-1323.
127. Wickham TJ, Mathias P, Cheres DA, Nemerow GR: **Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment.** *Cell* 1993, **73**(2):309-319.
128. Berkner KL, Sharp PA: **Generation of adenovirus by transfection of plasmids.** *Nucleic acids research* 1983, **11**(17):6003-6020.
129. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J: **Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery.** *J Clin Invest* 1993, **92**(2):883-893.
130. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM: **In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses.** *J Biol Chem* 1994, **269**(18):13695-13702.
131. Li J, Fang B, Eisensmith RC, Li XH, Nasonkin I, Lin-Lee YC, Mims MP, Hughes A, Montgomery CD, Roberts JD, Parker TS, Levine DM, Woo SL: **In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene.** *J Clin Invest* 1995, **95**(2):768-773.

132. Brown DR, Brousseau ME, Shamburek RD, Talley GD, Meyn S, Demosky SJ Jr, Santamarina-Fojo S, Brewer HB Jr, Hoeg JM: **Adenoviral delivery of low-density lipoprotein receptors to hyperlipidemic rabbits: receptor expression modulates high-density lipoproteins.** *Metabolism* 1996, **45**(12):1447-1457.
133. Heeren J, Steinwaerder DS, Schnieders F, Cichon G, Strauss M, Beisiegel U: **Nonphysiological overexpression of low-density lipoprotein receptors causes pathological intracellular lipid accumulation and the formation of cholesterol and cholesterol ester crystals in vitro.** *J Mol Med* 1999, **77**(10):735-743.
134. Cichon G, Willnow T, Herwig S, Uckert W, Loser P, Schmidt HH, Benhidjeb T, Schlag PM, Schnieders F, Niedzielska D, Heeren J: **Non-physiological overexpression of the low density lipoprotein receptor (LDLR) gene in the liver induces pathological intracellular lipid and cholesterol storage.** *The journal of gene medicine* 2004, **6**(2):166-175.
135. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM: **Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.** *Proc Natl Acad Sci USA* 1995, **92**(5):1401-1405.
136. Barr D, Tubb J, Ferguson D, Scaria A, Lieber A, Wilson C, Perkins J, Kay MA: **Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains.** *Gene Ther* 1995, **2**(2):151-155.
137. Stein CS, Martins I, Davidson BL: **Long-term reversal of hypercholesterolemia in low density lipoprotein receptor (LDLR)-deficient mice by adenovirus-mediated LDLR gene transfer combined with CD154 blockade.** *J Gene Med* 2000, **2**(1):41-51.
138. Wang Q, Finer MH: **Second-generation adenovirus vectors.** *Nature medicine* 1996, **2**(6):714-716.
139. Nomura S, Merched A, Nour E, Dieker C, Oka K, Chan L: **Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia.** *Gene therapy* 2004, **11**(20):1540-1548.
140. Jacobs F, Van Craeyveld E, Feng Y, Snoeys J, De Geest B: **Adenoviral low density lipoprotein receptor attenuates progression of atherosclerosis and decreases tissue cholesterol levels in a murine model of familial hypercholesterolemia.** *Atherosclerosis* 2008, **201**(2):289-297.
141. Oka K, Pastore L, Kim IH, Merched A, Nomura S, Lee HJ, Merched-Sauvage M, Arden-Riley C, Lee B, Finegold M, Beaudet A, Chan L: **Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor.** *Circulation* 2001, **103**(9):1274-1281.
142. Isner JM, Asahara T: **Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization.** *The Journal of clinical investigation* 1999, **103**(9):1231-1236.
143. Nathwani AC, McIntosh J, Davidoff AM: **An update on gene therapy for hemophilia.** *Curr Hematol Rep* 2005, **4**(4):287-293.
144. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, et al: **Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.** *Nature medicine* 2006, **12**(3):342-347.
145. Muzyczka N, Berns KI: **Parvoviridae, The viruses and their replication.** In *Fields Virology. Volume 2.* 4 edition. Edited by: Fields B, Knipe D, Howley P. Philadelphia: Lippincott-Williams and Wilkins; 1999:2327-2379.
146. Davidoff AM, Gray JT, Ng CY, Zhang Y, Zhou J, Spence Y, Bakar Y, Nathwani AC: **Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models.** *Mol Ther* 2005, **11**(6):875-888.
147. Davidoff AM, Ng CY, Zhou J, Spence Y, Nathwani AC: **Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway.** *Blood* 2003, **102**(2):480-488.
148. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF: **Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus.** *The Journal of clinical investigation* 2000, **105**(11):1573-1587.
149. Nathwani AC, Cochrane M, McIntosh J, Ng CY, Zhou J, Gray JT, Davidoff AM: **Enhancing transduction of the liver by adeno-associated viral vectors.** *Gene therapy* 2009, **16**(1):60-69.
150. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM: **Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis.** *Journal of virology* 1996, **70**(1):520-532.
151. Wang Z, Ma H, Li J, Sun L, Zhang J, Xiao X: **Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo.** *Gene therapy* 2003, **10**(26):2105-2111.
152. Nathwani AC, Gray JT, Ng CY, Zhou J, Spence Y, Waddington SN, Tuddenham EG, Kember-Cook G, McIntosh J, Boon-Spijker M, Mertens K, Davidoff AM: **Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.** *Blood* 2006, **107**(7):2653-2661.
153. Chen SJ, Rader DJ, Tazelaar J, Kawashiri M, Gao G, Wilson JM: **Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor.** *Mol Ther* 2000, **2**(3):256-261.
154. Leberer C, Gao G, Louboutin JP, Millar J, Rader D, Wilson JM: **Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia.** *J Gene Med* 2004, **6**(6):663-672.
155. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM: **Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.** *Proc Natl Acad Sci USA* 2002, **99**(18):11854-11859.
156. Kitajima K, Marchadier DH, Miller GC, Gao GP, Wilson JM, Rader DJ: **Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8.** *Arteriosclerosis, thrombosis, and vascular biology* 2006, **26**(8):1852-1857.
157. Liu Y, Li D, Chen J, Xie J, Bandyopadhyay S, Zhang D, Nemarkommula AR, Liu H, Mehta JL, Hermonat PL: **Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10.** *Atherosclerosis* 2006, **188**(1):19-27.
158. Yoshioka T, Okada T, Maeda Y, Ikeda U, Shimpo M, Nomoto T, Takeuchi K, Nonaka-Sarukawa M, Ito T, Takahashi M, Matsushita T, Mizukami H, Hanazono Y, Kume A, Ookawara S, Kawano M, Ishibashi S, Shimada K, Ozawa K: **Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice.** *Gene therapy* 2004, **11**(24):1772-1779.
159. Kassim SH, Li H, Vandenberghe LH, Hinderer C, Bell P, Marchadier D, Wilson A, Cromley D, Redon V, Yu H, Wilson JM, Rader DJ: **Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis.** *PLoS one* 2010, **5**(10):e13424.
160. Mueller C, Flotte T: **Clinical gene therapy using recombinant adeno-associated virus vectors.** *Gene Ther* 2008, **15**(11):858-863.
161. Kay MA, Glorioso JC, Naldini L: **Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics.** *Nature medicine* 2001, **7**(1):33-40.
162. Rohll JB, Mitrophanous KA, Martin-Rendon E, Ellard FM, Radcliffe PA, Mazarakis ND, Kingsman SM: **Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors.** *Methods Enzymol* 2002, **346**:466-500.
163. Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubel A, Spitz L, Lewis P, Goldfarb D, Emerman M, Stevenson M: **A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells.** *Nature* 1993, **365**(6447):666-669.
164. Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M: **Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection.** *Proceedings of the National Academy of Sciences of the United States of America* 1993, **90**(13):6125-6129.
165. Lewis PF, Emerman M: **Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus.** *J Virol* 1994, **68**(1):510-516.
166. Banasik MB, McCray PB Jr: **Integrase-defective lentiviral vectors: progress and applications.** *Gene therapy* 2010, **17**(2):150-157.
167. Pauza CD, Trivedi P, McKechnie TS, Richman DD, Graziano FM: **2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo.** *Virology* 1994, **205**(2):470-478.

168. Farnet CM, Haseltine WA: **Circularization of human immunodeficiency virus type 1 DNA in vitro.** *Journal of virology* 1991, **65**(12):6942-6952.
169. Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, Nuttin B, Debysers Z: **Characterization of lentiviral vector-mediated gene transfer in adult mouse brain.** *Hum Gene Ther* 2002, **13**(7):841-853.
170. Baekelandt V, Eggermont K, Michiels M, Nuttin B, Debysers Z: **Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain.** *Gene Ther* 2003, **10**(23):1933-1940.
171. O'Rourke JP, Hiranagi H, Urban K, Patel M, Olsen JC, Bunnell BA: **Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentiviral vectors.** *Mol Ther* 2003, **7**(5 Pt 1):632-639.
172. Park F, Ohashi K, Kay MA: **Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver.** *Blood* 2000, **96**(3):1173-1176.
173. Zhao J, Pettigrew GJ, Thomas J, Vandenberg JI, Delriviere L, Bolton EM, Carmichael A, Martin JL, Marber MS, Lever AM: **Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo.** *Basic Res Cardiol* 2002, **97**(5):348-358.
174. Philippe S, Sarkis C, Barkats M, Mammeri H, Ladrone C, Petit C, Mallet J, Serguera C: **Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo.** *Proceedings of the National Academy of Sciences of the United States of America* 2006, **103**(47):17684-17689.
175. Philpott NJ, Thrasher AJ: **Use of nonintegrating lentiviral vectors for gene therapy.** *Human gene therapy* 2007, **18**(6):483-489.
176. Yanez-Munoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, Buch P, MacLaren RE, Anderson PN, Barker SE, Duran Y, Bartholomae C, von Kalle C, Heckenlively JR, Kinnon C, Ali RR, Thrasher AJ: **Effective gene therapy with nonintegrating lentiviral vectors.** *Nature medicine* 2006, **12**(3):348-353.
177. Jenke AC, Scinteie MF, Stehle IM, Lipps HJ: **Expression of a transgene encoded on a non-viral episomal vector is not subject to epigenetic silencing by cytosine methylation.** *Molecular biology reports* 2004, **31**(2):85-90.
178. Wanisch K, Yanez-Munoz RJ: **Integration-deficient lentiviral vectors: a slow coming of age.** *Mol Ther* 2009, **17**(8):1316-1332.
179. Rahim AA, Wong AM, Howe SJ, Buckley SM, Acosta-Saltos AD, Elston KE, Ward NJ, Philpott NJ, Cooper JD, Anderson PN, Waddington SN, Thrasher AJ, Raivich G: **Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors.** *Gene therapy* 2009, **16**(4):509-520.
180. Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP, Thrasher AJ, Collins MK, Philpott NJ: **Stable gene transfer to muscle using non-integrating lentiviral vectors.** *Mol Ther* 2007, **15**(11):1947-1954.
181. Bayer M, Kantor B, Cockrell A, Ma H, Zeithaml B, Li X, McCown T, Kafri T: **A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector.** *Mol Ther* 2008, **16**(12):1968-1976.
182. Al-Allaf F: **Construction and analyses of EIAV-based Lentivirus vectors for fetal gene therapy of familial hypercholesterolaemia and haemophilia-B.** London: Imperial College Faculty of Medicine, University of London; 2004.
183. Wang L, Takabe K, Bidlingmaier SM, Illi CR, Verma IM: **Sustained correction of bleeding disorder in hemophilia B mice by gene therapy.** *Proceedings of the National Academy of Sciences of the United States of America* 1999, **96**(7):3906-3910.
184. Kankkonen HM, Vahakangas E, Marr RA, Pakkanen T, Laurema A, Leppanen P, Jalkanen J, Verma IM, Yla-Herttuala S: **Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy.** *Mol Ther* 2004, **9**(4):548-556.
185. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD: **Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences.** *PLoS biology* 2004, **2**(8):E234.
186. Rohdewold H, Weiher H, Reik W, Jaenisch R, Breindl M: **Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites.** *Journal of virology* 1987, **61**(2):336-343.
187. Varmus HE, Padgett T, Heasley S, Simon G, Bishop JM: **Cellular functions are required for the synthesis and integration of avian sarcoma virus-specific DNA.** *Cell* 1977, **11**(2):307-319.
188. Wu X, Li Y, Crise B, Burgess SM: **Transcription start regions in the human genome are favored targets for MLV integration.** *Science (New York, NY)* 2003, **300**(5626):1749-1751.
189. Laufs S, Guenechea G, Gonzalez-Murillo A, Zsuzsanna Nagy K, Luz Lozano M, del Val C, Jonnakuty S, Hotz-Wagenblatt A, Jens Zeller W, Bueren JA, Fruehauf S: **Lentiviral vector integration sites in human NOD/SCID repopulating cells.** *The journal of gene medicine* 2006, **8**(10):1197-1207.
190. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F: **HIV-1 integration in the human genome favors active genes and local hotspots.** *Cell* 2002, **110**(4):521-529.
191. Grososky AJ, Skandalis A, Hasegawa L, Walter BN: **Insertional inactivation of the tk locus in a human B lymphoblastoid cell line by a retroviral shuttle vector.** *Mutation research* 1993, **289**(2):297-308.
192. King W, Patel MD, Lobel LI, Goff SP, Nguyen-Huu MC: **Insertion mutagenesis of embryonal carcinoma cells by retroviruses.** *Science (New York, NY)* 1985, **228**(4699):554-558.
193. Stocking C, Bergholz U, Friel J, Klingler K, Wagener T, Starke C, Kitamura T, Miyajima A, Ostertag W: **Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid stem cell line.** *Growth factors (Chur, Switzerland)* 1993, **8**(3):197-209.
194. Themis M, May D, Coutelle C, Newbold RF: **Mutational effects of retrovirus insertion on the genome of V79 cells by an attenuated retrovirus vector: implications for gene therapy.** *Gene therapy* 2003, **10**(19):1703-1711.
195. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bouso P, Deist FL, Fischer A: **Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.** *Science (New York, NY)* 2000, **288**(5466):669-672.
196. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K, Asnafi V, MacIntyre E, Dal Cortivo L, Radford I, Brousse N, Sigaux F, Moshous D, Hauer J, Borkhardt A, Belohradsky BH, Wintergerst U, Velez MC, Leiva L, Sorensen R, Wulffraat N, Blanche S, Bushman FD, Fischer A, Cavazzana-Calvo M: **Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.** *The Journal of clinical investigation* 2008, **118**(9):3132-3142.
197. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M: **Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.** *The New England journal of medicine* 2002, **346**(16):1185-1193.
198. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempki H, Brugman MH, Pike-Overzet K, Chatters SJ, de Ridder D, Gilmour KC, Adams S, Thornhill SJ, Parsley KL, Staal FJ, Gale RE, Linch DC, Bayford J, Brown L, Quaye M, Kinnon C, Ancliff P, Webb DK, Schmidt M, von Kalle C, Gaspar HB, Thrasher AJ: **Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.** *The Journal of clinical investigation* 2008, **118**(9):3143-3150.
199. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kuhlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Luthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M: **Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EV11, PRDM16 or SETBP1.** *Nature medicine* 2006, **12**(4):401-409.
200. Aiuti A, Roncarolo MG: **Ten years of gene therapy for primary immune deficiencies.** *Hematology/the Education Program of the American Society of Hematology American Society of Hematology* 2009, 682-689.
201. Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA, von Kalle C: **Side effects of retroviral gene transfer into hematopoietic stem cells.** *Blood* 2003, **101**(6):2099-2114.
202. Li Z, Dullmann J, Schiedmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kuhlcke K, Eckert HG, Fehse B, Baum C: **Murine leukemia induced by retroviral gene marking.** *Science (New York, NY)* 2002, **296**(5567):497.
203. Modlich U, Kustikova OS, Schmidt M, Rudolph C, Meyer J, Li Z, Kamino K, von Neuhoff N, Schlegelberger B, Kuehlicke K, Bunting KD, Schmidt S, Deichmann A, von Kalle C, Fehse B, Baum C: **Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis.** *Blood* 2005, **105**(11):4235-4246.
204. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi L, Benedicenti F, Ambrosi A, Di Serio C, Dogliani C, von Kalle C, Naldini L: **Hematopoietic stem cell gene transfer in a tumor-prone**



- mouse model uncovers low genotoxicity of lentiviral vector integration. *Nature biotechnology* 2006, **24**(6):687-696.
205. Nienhuis AW, Dunbar CE, Sorrentino BP: **Genotoxicity of retroviral integration in hematopoietic cells.** *Mol Ther* 2006, **13**(6):1031-1049.
206. Baum C, von Kalle C, Staal FJ, Li Z, Fehse B, Schmidt M, Weerkamp F, Karlsson S, Wagemaker G, Williams DA: **Chance or necessity? Insertional mutagenesis in gene therapy and its consequences.** *Mol Ther* 2004, **9**(1):5-13.
207. Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Grassman E, Mishra A, Baum C: **Physiological promoters reduce the genotoxic risk of integrating gene vectors.** *Mol Ther* 2008, **16**(4):718-725.
208. Waddington SN, Mitrophanous KA, Ellard FM, Buckley SM, Nivsarkar M, Lawrence L, Cook HT, Al-Allaf F, Bigger B, Kingsman SM, Coutelle C, Themis M: **Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice.** *Gene therapy* 2003, **10**(15):1234-1240.
209. Waddington SN, Nivsarkar MS, Mistry AR, Buckley SM, Kembal-Cook G, Mosley KL, Mitrophanous K, Radcliffe P, Holder MV, Brittan M, Georgiadis A, Al-Allaf F, Bigger BW, Gregory LG, Cook HT, Ali RR, Thrasher A, Tuddenham EG, Themis M, Coutelle C: **Permanent phenotypic correction of Hemophilia B in immunocompetent mice by prenatal gene therapy.** *Blood* 2004, **104**(9):2714-2721.
210. Themis M, Waddington SN, Schmidt M, von Kalle C, Wang Y, Al-Allaf F, Gregory LG, Nivsarkar M, Themis M, Holder MV, Buckley SM, Dighe N, Ruthe AT, Mistry A, Bigger B, Rahim A, Nguyen TH, Trono D, Thrasher AJ, Coutelle C: **Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice.** *Mol Ther* 2005, **12**(4):763-771.
211. Khoo B, Roca X, Chew SL, Krainer AR: **Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.** *BMC molecular biology* 2007, **8**:3.
212. Lauf S, Gentner B, Nagy KZ, Jauch A, Benner A, Naundorf S, Kuehlcke K, Schiedlmeier B, Ho AD, Zeller WJ, Fruehauf S: **Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells.** *Blood* 2003, **101**(6):2191-2198.
213. Lauf S, Nagy KZ, Giordano FA, Hotz-Wagenblatt A, Zeller WJ, Fruehauf S: **Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.** *Mol Ther* 2004, **10**(5):874-881.
214. Schuettrumpf J, Liu JH, Couto LB, Addya K, Leonard DG, Zhen Z, Sommer J, Arruda VR: **Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial.** *Mol Ther* 2006, **13**(6):1064-1073.
215. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DG, Johnson FA, McClelland A, Scallan C, Skarsgard E, Flake AW, Kay MA, High KA, Glader B: **AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.** *Blood* 2003, **101**(8):2963-2972.
216. Kobayashi K, Oka K, Forte T, Ishida B, Teng B, Ishimura-Oka K, Nakamura M, Chan L: **Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor.** *The Journal of biological chemistry* 1996, **271**(12):6852-6860.
217. Marlovits TC, Abrahamsberg C, Blaas D: **Very-low-density lipoprotein receptor fragment shed from HeLa cells inhibits human rhinovirus infection.** *Journal of virology* 1998, **72**(12):10246-10250.
218. Matri J, Chuah M, VandenDriessche T: **Recent Advances in Lentiviral Vector Development and Applications.** *Mol Ther* 2010, **18**(5):477-490.

doi:10.1186/1755-7682-3-36

**Cite this article as:** Al-Allaf et al.: LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. *International Archives of Medicine* 2010 3:36.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

